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The goal of the field of Bioengineering has always been to bring about a better standard 
of care for patients.  As a field encompassing a broad array of researchers and talents, 
such improvements often are brought about through the integration of different fields.  
This work advances the integration of controlled delivery and chemotherapy.  The use of 
cytotoxic chemotherapy has become and will continue to be a powerful tool for the 
treatment of solid malignancies. Conventional dose scheduling of cytotoxic agents and 
newer biological response modifiers are investigated under a clinical paradigm initially 
designed to identify a drug dose that elicits acceptable levels of toxicity before the 
rigorous testing of efficacy.  Newly developed regimens involving altering of the 
conventional scheduling are always compared to the current “gold standard” of 
chemotherapy.  This process of evaluation becomes quite cost prohibitive through the 
number of clinical trials required, and often the “clinically meaningful endpoint” is no 
longer overall survival, but some more specific event, e.g. the targeted death of a specific 
type of cell.  The traditional method for evaluating new anti-cancer drugs is appropriately 
intended to minimize patient toxicity and optimize safety.  However, the inherent flaw in 
this approach is that the effective dose and the toxic dose are often not concurrently 
considered (e.g. the therapeutic index); rather, the approach is geared toward maximizing 
death of a particular cell type. That is, the traditional approach is to provide the maximum 
tolerated dose at defined time intervals; the intervals allow recovery of the normal tissue 
but they also provide time for tumor cell regrowth and potential chemo-resistance.  
Another obstacle is the conventional (intravenous) routes of administration which often 
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expose the tumor to relatively short durations of drug, based on half-lives at excessively 
high systemic levels; toxicity is cumulative and associated with high systemic levels of 
drug.  The theoretical benefits of controlled drug delivery can minimize significant 
fluctuations in systemic toxicity while optimizing efficacy.  Such controlled therapy 
requires a defined therapeutic index and a delivery platform that can be tailored to meet 
the desired clinical endpoint.  As understanding of cancer has grown, novel strategies 
have been developed to selectively administer conventional chemotherapy to manage 
advanced cases of solid malignancies that historically have a poor prognosis. The largest 
obstacle to the use of such approaches is the dearth of technology for delivering a 
chemotherapeutic in a repeatable controlled manner. To date, there is a paucity of 
existing biomaterials whose properties allow (1) in situ gelation kinetics that can be 
modulated to produce a predictable and sustainable drug delivery depot, (2) the ability to 
control in situ gelation kinetics to maximize vascular and micro-vascular access to the 
tumor, (3) predictable controlled release kinetics and duration of release in concert with 
the total drug load to minimize dose dumping and maximize release, (4) and modulated 
absorption kinetics to minimize collateral damage to healthy tissue and facilitate repeat 
administration  based on tumor response or treatment requirements.  
 
At Poly-Med Incorporated, the OC Polymer system was specifically designed to combat 
current issues with chemotherapy. These polymers, when combined in a novel delivery 
system, allow localized controlled delivery.  The system advanced in this work is 
comprised of the OC polymer, solubilized in a low molecular weight polyethylene glycol, 
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and further absorbable polymers to help modulate release.  This system is injectable 
through a standard Leur-Lok needle and syringe system and forms a stable depot after 
injection into an aqueous environment. The primary objective of the work was to test the 
OC delivery system in an in vitro and an in vivo setting, laying the foundation for 
investigation of this system in multiple chemotherapeutic treatments.  The specific aims 
of the project were to (1) determine the potential efficacy of the system through the 
performance in in vitro studies to determine release characteristics with a model drug; (2) 
ensure the relevancy of the results to a chemotherapy-based system through further in 
vitro testing with the platinum-based chemotherapeutic carboplatin; and (3) exhibit the 
clinical potential of the product through in vivo testing of a promising OC system in two 
administration methods using a mouse flank model.   
 
The OC polymer system was examined for release in vitro and was shown capable of 
release of a water-soluble model drug from 3 days to greater than 45 days.  Also, the OC 
system was shown capable of release of the chemotherapeutic carboplatin in a relatively 
linear manner over a period of 3 weeks, the course of a typical chemotherapeutic 
regimen.  Finally, the OC polymer system was examined in an in vivo model and 
tolerance of the non-drug loaded system was exhibited.  Also, mice were shown to 
tolerate higher levels of total carboplatin exposure than the literature suggested LD50 of 
150 mg/kg.  The next steps in preparing such a system involve further in vitro studies and 
in vivo testing to validate the efficacy of such a system prior to clinical trials.         
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support this endeavor would not have been possible.   
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This dissertation describes the development of a drug delivery system through the early 
stages of design, in vitro testing and in vivo screening.  The chapters each represent a 
different stage of that process, and are outlined in the 
Figure provided. Chapter 1 provides a general 
overview of cancer and chemotherapy.  Specifically, 
many different chemotherapy agents are reviewed for 
clinical significance.  Chapter 2 further elucidates the 
background of the field through a review of 
oncological methods.  New and novel methods and 
technologies are reviewed.  Chapter 3 provides the 
background on the OC system iteself.  The polymers 
involved are discussed and characterized, and a 
representative polymer is advanced.  In Chapter 4, 
release is explored from the OC system, with the 
model drug doxycycline.  Release is studied from 
many different configurations of the system, showing 
the modularity of the platform as a whole.  Chapter 5 further illustrates the modularity of 
the system with the use of many different pharmacuetics in regards to release.  These 
studies were designed to show the many different indications for which the system can be 
used.  Finally, Chapter 6 details the in vivo work performed.  Preliminary studies, assay 
exploration and a maximum tolerated dose study are all recorded to lay the ground work 
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for a future full-scale animal study.  Portions of many of these chapters have been 
published in the following: 
 
“Intravaginal Drug Delivery” in Polymers for Vascular and Urogenital Applications 
(S.W. Shalaby, K.J.L. Burg, W.S. Shalaby, eds.) J. M. Olbrich,  W.S. Shalaby,  G.H. 
Hilas. Taylor & Francis Group, LLC (2012) 
 
“Injectable In Situ Forming Controlled Release Implant Composed of A Poly-Ether-
Ester-Carbonate and Applications in the Field of Chemotherapy” J.  Olbrich, P. Tate, J. 
Corbett, J. Lindsey, III, S.  Nagatomi, W. Shalaby, S. Shalaby Journal of Biomedical 
Materials Research A (2012) 2012 Sep;100(9):2365-72 
 
“Development and Utilization of Reversed Phase High Performance Liquid 
Chromatography Methods for a Series of Therapeutic Agents” J. Olbrich and J. Corbett 
Modern Chemistry & Applications (2013) 1:2 
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One malady has hung over society more than any other in the history of modern 
medicine.  Cancer has seen a steady increase over the years; one out of every two 
children born today will be diagnosed with the disease at some point in their lives
1
.  
Malignant tumors can manifest in almost any system in the human body and, untreated, 
will metastasize to other organs and tissues leading inevitably to death of the host.  The 
mortality of the disease and the lack of a “cure” lead to the vital necessity of effective 
treatments.  Treatments will vary slightly depending on the area of affliction; however 
they commonly consist of surgery, radiation and chemotherapy
2
.  Surgery is the first line 
of defense against most operable tumors and is usually at least partially effective against 
localized, relatively early stage cancers
3,4
.  However, in patients with recurrent tumors or 
tumors in inoperable areas, chemotherapy is indicated or possibly the only option
3,5
.   
 
Chemotherapy has evolved over the years, and is generally considered to originate in the 
period surrounding World War II (1939-1945).  After observing rapid tissue growth 
brought on by unchecked cell proliferation, Louis Goodman and his group at Yale 
University investigated means to slow this phenomenon
6
.  The effect of a toxic agent 
used in the war, mustard gas, was studied and found to retard the growth.  Concurrently, a 
group at Harvard University examined means with which to synthesize antagonists for 
tumor growth.  Their work culminated with the development of one of the first 
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synthesized folic acid antagonists, aminopterin
7
.  This discovery lead to significant 
success in treating lymphomas and pediatric acute leukemia.    
 
Despite the evidence presented in Farber’s publication, skepticism remained prevalent in 
the field toward the effectiveness of aminopterin and the next generation amethopterin.  It 
took fully a decade more before solid evidence came forward describing the effectiveness 
of these antagonists, specifically amethopterin (modern methotrexate) in combating 
unrestricted cellular growth
8
.  More significant than the proof of folic acid antagonists 
was the fact that researchers at the National Cancer Institute were able to force a solid 
tumor into remission for the first time using chemotherapeutic agents.  Methotrexate 




Chemotherapeutics became an area of intense interest for research, both public and 
private.  The first alkaloid chemotherapeutic, Vinblastine, was independently developed 
in 1958 at both Eli Lilly and the University of Western Ontario
10
.  The alkaloid group of 
drugs was significant because their 
mechanism of action differed from that 
of methotrexate in that they interfered 
with tubulin.  This in turn disrupted 
microtubule production during 
mitosis, and hence retarded cellular 
reproduction.  This development gave 




rise to a revolution in the field of chemotherapeutics, leading to drugs designed to 
interfere with the mitotic process rather than design of simple antagonists such as 
methotrexate. 
 
The next key breakthrough in the development of chemotherapy was the concept of 
combination therapy, or the use of multiple drugs against a single tumor.  Combination 
therapy relies on the principle of “multiple pathways”, meaning that, should an individual 
tumor develop a resistance or immunity to a certain type of chemotherapeutic, the 
treatment paradigm also contains a complimentary drug that acts through a differing 
mechanism.  In this way the tumor is theoretically always subjected to an effective 
chemotherapeutic drug. 
 
However, even with combination therapy, large volume or advanced stage disease would 
be refractive to treatment.  Time and time again it has been proven that chemotherapy is 
more effective against smaller groups of cells, perhaps because most chemotherapeutic 
agents are more effective against mitotic cells than cells in the resting phase
11
 and larger, 
more developed tumors will have a smaller percentage of cells undergoing mitosis at any 
one time. Due to the relative ineffectiveness of chemotherapeutics in affecting medium 
and advanced stage tumors, chemotherapy is often combined with other methods 
12
.  This 
combination is referred to as adjuvant therapy, which infers any combination of surgery, 
chemotherapy, radiotherapy, or hormonal therapy to combat cancerous growths.  
 4 
Adjuvant therapy is the modern primary care paradigm for most operable tumors such as 




Modern chemotherapy revolves around adjuvant therapies with multiple different drugs.  
Over the years, different families of chemotherapeutic drugs have been developed.  Some 
of the more commonly used among these are the taxanes, anthracyclines, and platinum-
based drugs.  Upon diagnosis, attending physicians design the best course of treatment 
for each individual and choose the components of adjuvant therapy and the drugs used 
based on previous clinical data. 
 
Types of Cancer 
Proper and prompt diagnosis of cancer is the most vital step in combating the disease.  
Local cancers have been documented as appearing in almost every organ in the human 
body.  Of all cancers diagnosed in the United States, at least one out of every two is 
defined as lung, female breast, prostate, or colorectal
14
.  These cancers are colloquially 
referred to as the “Big 4” cancers.  Appropriately, a significant portion of research and 
development funding is directed at each of these diseases. 
 
Lung cancer affects nearly 7% of the American population during their lifetime according 
to 2011National Cancer Institute statistics
1
.  Lung cancer is divided into Small Cell Lung 
Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma (NSCLC).  NSCLC accounts 




.  Due to the nature of the disease, specifically the presentation of a tangible 
tumor, surgery is usually the primary mode of treatment
16
.  However, this treatment only 
results in a 20 to 30% survival rate.  Early detection and adjuvant therapy including 
radio- or chemotherapy can improve this rate, but NSCLC mortality rates remain high 
even with such treatment.  Chemotherapeutic agents used in conjunction with surgery 
include taxane, pyrimidines, camptothecin analogues, vinorelbine, and platinum 
combinations thereof
17
.  SCLC is more difficult to operate upon and responds better to 
primary chemotherapy than NSCLC, with upwards of a 45% survival rate.  Surgery can 




While lung cancer is the leading cause of death by cancer in males, breast cancer claims 
more females every year than any other form of cancer
1
.   Breast cancer usually manifests 
itself within the mammary areas of the breast. As recently as 1980, the main method for 
treatment was mastectomy, in which the cancerous portion of the breast was removed as 
well as a majority of the surrounding tissue, the latter as a prophylactic measure
19
.  Due 
to the high public profile of the disease, a large amount of funding and research targets 
this area.  Through research and the advent of screening technologies, multiple new 
avenues are available for treatment, and mastectomy has been restricted to preventative 
measures and “last resort” cases.  Simple radiotherapy or primary chemotherapy is 
capable of inducing tumor remission or at least requiring only a partial mastectomy, 
leaving a cosmetically acceptable breast
4, 20
.  Early screening procedures have provided 
the largest opportunity to combat breast cancer non-operatively, by allowing 
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chemotherapeutics to be used in the early stages of the disease
21
.  Indeed, the paradigm 
for treating breast cancer calls for early detection and primary treatment with drugs such 
as doxorubicin or paclitaxel
22
.  If the primary treatment is not entirely successful, surgery 
can be used to augment chemotherapy; this approach is called neoadjuvant therapy
23
.  
Other less traditional treatment mechanisms include hormonal therapy, oral 
chemotherapy, and anti-angiogenesis therapy
24, 25
.  Each of these treatments, while 
originating in breast cancer treatment, is beginning to gain traction in other areas of 
cancer research. 
 
The third “Big 4” cancer is cancer of the prostate.  Affecting mainly the male organ used 
in reproduction, this disease will affect 16% of men at some point during their lives
1
.  
Myriad prostate cancer treatments have been developed over the years, but few have been 
proven repeatedly effective
26
.  The most common primary treatment is surgery
27
.  The 
procedure, radical prostatectomy, is intended to remove or reduce the cancerous tissue
28
.  
Other options range from hormonal therapy, to radio therapy, to active non-action 
(“Watchful Waiting”)
 29
.  Chemotherapy has been largely ineffective in the realm of 
prostate cancer, but recent studies with the taxanes have shown promise
30
.  Because of 
the absence of effective chemotherapy, the leading adjunctive therapy is hormonal.  
Hormonal therapies, such as those including antiandrogens, are as effective as castration 
in arresting prostate cancer
31
.  The quality of life advantages of this treatment far exceed 
castration, in at least the obvious matter of retaining sexual function.  However, the 
largest recent contribution to the battle against this disease has come in the form of 
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enhanced screening and early detection.  Prostate-specific antigen (PSA) is a protein, the 
level of which can be monitored to allow extremely early detection of prostate 
problems
32
.  Over half of prostate issues detected by this mechanism can be readily 
treated.  Cancer allowed to progress past this stage, often to hormone refractory prostate 
cancer which cannot be treated by castration or hormone therapy, is often terminal.  In 
the absence of a highly effective treatment, early detection is by far the best available 
practice for combating this disease. 
 
The final, and perhaps least publicized, of the Big 4 cancers is colorectal cancer.  In this 
instance, carcinomas develop from polyps within the intestinal tract
33
.  While not all 
polyps will develop into carcinomas, the most effective way to treat colorectal cancer is 
to identify and swiftly deal with those polyps which have the potential to proliferate in a 
malignant manner.  When early detection fails, colorectal cancer often leads to a poor 
prognosis as the highly vascularized nature of the area allows quick and widespread 
metastization
33
.     Many individuals are reluctant to undergo screening
33, 34
; this failure to 
seek medical screening largely contributes to colorectal cancer’s moniker “the silent 
killer”.  When the disease is allowed to progress, surgery is the frontline treatment 
prescribed in the majority of cases
35, 36, 37
.  Prior to metastasis, when tumors are relatively 
small, surgical treatment for colorectal cancer has a relatively high success rate
35
.  This 
success rate can be enhanced by radiologic imaging techniques which include barium 
enemas prior to positron emission tomography (PET)
 38
.  These radiographic techniques 
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are particularly useful in the colorectal arena due to the non-uniform nature of the lower 
intestinal tract. 
 
Secondary treatment, where surgery alone is not successful, usually focuses on adjuvant 
therapy using chemo- or radiotherapy, with physicians often favoring anti-neoplastic 
drugs
37
.  The current paradigm of chemotherapy for colorectal cancer is seen in the form 
of the drug 5-fluorouracil, a fluoropyrimidine which is capable of oral administration
39, 40
.  
This drug, which disrupts deoxyribonucleic acid (DNA) replication and thus cell division, 
has been shown to combat localized forms of colorectal cancer as well as metastasized 
forms of the disease
40
.  Accordingly, oral fluorouracil is often employed in conjunction 
with surgery in frontline treatment for colorectal cancer, which is detected only at a late, 
aggressive stage.  Other chemotherapeutics have been developed
39
, mostly within the 
fluoropyrimidine family, but 5-fluorouracil remains the chemotherapy of choice for 
colorectal cancer. 
 
Aside from the aforementioned “Big 4” group of cancers, carcinomas can manifest 
themselves in almost any organ of the body.  Perhaps the deadliest area for cancer to 
develop is within the cranial cavity.  Rarely developing spontaneously, brain cancer often 
is the result of metastasis of another cancer, such as that of the breast or lung
41, 42, 43, 44
.  
Unlike other cancers, surgery is only a viable option in about 25% of cases
45
.  Lack of 
suitability for surgical treatment
49
 means that chemotherapy
43, 45
 and, to a lesser extent, 
radiotherapy
42
, are the frontline treatments for brain cancer.  Indeed, chemotherapy is 
 9 





While the necessity of chemotherapy in cases of brain cancer is obvious, the 
methodology is not.  The lipophilic nature of the blood-brain barrier (BBB) is seen as a 
deterring factor in the delivery of almost any water-soluble anti-neoplastic
43
 and, as such, 
systemic delivery of lipophilic drugs will often preferentially deliver to sites other than 
the brain
47
.  To this end, direct injection and implantation of delivery vectors such as drug 
loaded “wafers” have been investigated
43, 47
.  Regrettably, even with these theoretically 
more efficient methods, drug delivery to the brain remains difficult
48
.  Great advances 
will be needed in the coming decade to improve the poor mortality rates (around 80%) 




Brain cancer can occasionally be caused by the metastasis of ovarian cancer
51
.  Ovarian 
cancer is an important malady as it is the highest gynecological cause of death among 
women
52
.  While the origins of this disease are not fully understood, carcinomas in the 
ovary and surrounding tissue are thought to stem from hormonal imbalances/inductions
53
.  
Further complicating the issue is the high rate of metastasis and secondary cancers, 
thought to be brought about by cellular transport through the lymphatic drainage system, 
the latter which is prevalent in the gynecologic region
54
.   
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Ovarian cancer treatments often use chemotherapy as a frontline option, due to the high 
rate of metastasis and difficulty of surgery
55
.  The current paradigm relies on the use of a 
taxane, usually paclitaxel, in conjunction with a platinum drug
56, 57, 58, 59
.  Other drugs, 
such as doxorubicin, can be used as long as their toxicity levels are held in check
60
.  One 
such method for reducing toxicity that has been studied effectively in ovarian cancer is 
dose-dense therapy
61, 62, 63
.  This therapy relies on the shortening of the treatment window 
and the use of lower doses of drug.  Other treatments have been attempted, such as 
administration of vascular endothelial growth factor (VEGF) or retinoid analogs in order 
to circumvent traditional chemotherapeutic toxicity
64, 65
.  However, these therapies have a 
toxic effect, as is expected from almost any anti-angiogenic treatment
66
.  Further work is 




Any discussion of cancers would be incomplete without inclusion of skin cancer, the 
most common cancer in man
68
.  While this disease is largely treatable, with lower than 
average mortality rates among cancers, it will afflict large proportions of the population 
during their lives
69
.  While skin cancer is largely initiated by overexposure to ultraviolet 
radiation in the form of sunrays, it can still afflict humans with higher proportions of 
pigmentation in their skin
69,70
.  Also, some sections of the population will be more 
susceptible to developing the more malignant forms of this cancer based on genetic 
disposition
71
.  The deadliest form of skin cancer is a malignant melanoma. 
 
 11 
Malignant melanomas will account for less than 2% of cancers annually
72
, but if the 
disease is not caught in the early stages, the 5-year survival rate shrivels to less than 
10%
73
.  If caught early, surgery and palliative treatment can often be enough to check the 
growth of the tumor; however, as the disease progresses metastasis occurs
72
.  Malignant 
melanomas are among the most aggressive of all cancers in terms of metastasis, hence the 
need for early detection and treatment
73
.  Following this metastasis, there is still no clear 
path for treatment as most therapies in use are poorly tolerated or produce unacceptably 
low rates of success
74
.  Therapies such as retinoid chemotherapy
75
 and molecular/gene 
therapy
76,77
 have been used to attempt to combat melanoma metastasis.  However, the 
current benchmark for success uses systemic distribution of platinum or nitrosourea drugs 
to attempt to halt and force recession of the aggressive cancer
74
.  Due to the generally 
poor prognosis, current detection is more important in this case than in almost any other 
cancerous case, due to the dramatic difference between early and late detection survival 
rates.  Future work in the battle against metastasized melanomas will focus on more 
effective administration of systemic chemotherapeutic/gene therapy. 
 
For the past hundred years cancer has predominantly been treated with surgical 
resection
78
.  However, a shift towards non-surgical techniques is occurring, with 
promising results.  More and more commonly, chemotherapy is being used to treat 
cancer.  Increases in lifespan and elimination of malignant tissue have been realized in all 
age groups, even in pediatric groups
79
.  Chemotherapy is administered in myriad ways, 
including orally, intravenously, subcutaneously and intralesionally
78, 79, 80
.  The treatment 
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can be used independently in the frontline, adjuvantly (following surgery), concurrently 
with surgery or radiotherapy, or as a method of last resort (salvage therapy)
 78, 79
.  The 




Chemotherapy offers advantages over traditional surgical, and even radiological 
techniques
81
.  These benefits largely stem from the mechanism of action, as 
chemotherapy targets cells mainly during the proliferative stage.  Thus, by interfering 
with the reproduction of cells, the growth of large, fast-growing populations of cells can 
be checked or the cells may even be forced to recede.  One of the distinguishing elements 
of tumor cells is that they reproduce more quickly than normal human cells.  Therefore, 
by administering an agent which disrupts cells during this phase of cell life, cancer cells 
can be targeted preferentially over normal human cells.  Because of this induction of cell 




It is important to understand the types of agents used to undertake this treatment, as they 
all differ in properties and mechanism of action.  While most act to disrupt cell division 
in some way, different groups of drugs act in different manners.  Similar to selecting an 
antibiotic, choosing the correct drug often makes the difference between success and 
failure of a given treatment.  There are nine major families of cytotoxic drugs. 
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Alkylating agents are among the most widely used chemotherapeutics, due to their broad 
spectrum of action
83, 84
.  This class of drugs, comprising mainly cyclophosphamide and 
ifofsamide, acts mainly by covalently binding to exposed DNA, hence halting or 
disrupting the replication of cells.  These drugs are regarded for their large therapeutic 
window
85,86
 which allows lessening of virulent side-effects during use.  Another 
interesting attribute of these drugs is that their mechanism of action has been shown to be 
catalyzed through an increase in heat; as increased temperature (hyperthermia) is often a 
condition surrounding malignant tumors, this characteristic serves to increase the 
alkylating agent’s effectiveness
87
.  Further use of the alkylating agents, 
cyclophosphamide especially, is in metronomic dosing.  This dosing schedule entails the 
use of a more frequent, less intense treatment.  Cyclophosphamide has exhibited anti-
angiogenic properties which add even further to the effectiveness of the drug
88
.  This 
class of drugs is not without drawbacks, among which are low selectivity and targeting 
ability for cancerous cells and the quick inducement of tumor resistance
83
.  However, 
numerous studies have shown one alkylating agent to be effective against tumor growth 
once the tumor has become resistant to the other
89
.  Thus these agents are indicated as 















 and ovarian 
cancer
84,92





Figure 1.2: Carboplatin, the second 
generation member of the platinum drug 
family (Source: 
www.chemistry.about.com) 
Another family of chemotherapeutics, 
often used in combination with the 
alkylating agents
92
, is the platinum 
family of drugs.  This family consists 
of three generations of drugs.  The first, 
cisplatin, is among the most active 
agents used in the field
95
.  The second 
generation drug, carboplatin (Figure 2) 
has fast gained notoriety as being much 
more stable and as having fewer and milder side effects than cisplatin
96
.  The third 
generation, and most cytotoxic, platinum drug is oxaliplatin
97, 98
.  While the mechanism 
through which these drugs prove effective is not fully understood, it is theorized to 
involve the binding of the eponymous platinum group of the drugs to DNA
99, 100
.  The 
bound drug then prevents translation and transcription, effectively halting mitosis.  The 
drawback of this family lies in its higher than normal systemic toxicity
95
 and the fact that 
platinum resistance is inherent in many cancer lines
95, 96
.  This platinum resistance is 
normally presented by the detoxification of the drug by the tripepetide glutathione, which 
is normally tasked with mitigating metals
101
.  However, oxaliplatin has been shown to be 
efficacious where cis- carboplatins are found ineffective
98
, and all of the platinum drugs 
can be combined with glutathione inhibitors to increase their effect
101
.  These drugs are 
administered through a wide range of routes, including intravenous, intraperitoneal, and 
subcutaneous
102
. Because of the wide range of delivery options and a broad spectrum of 
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action, platinum drugs are used in combination and single agent therapies for a wide 













Another group of cytotoxic drugs developed out of everyday antibiotics.  The anti-tumor 
antibiotics work through DNA disruption, similar to the previously described groups, but 
do so in non-covalent binding manners
108
.  Cultivated from natural means, hence the 
antibiotic distinction
108, 109
, these are among the oldest anti-neoplastic drugs
110
.  The 
drugs included in the category include actinomycin-D, doxorubicin, and bleomycin.  
While distinct for their wide range of efficacy, these drugs are also noted for their 
exceptional systemic toxicity issues, even among chemotherapeutics
109, 110
.  This toxicity 
usually manifests in the areas of the heart and lung and poses a significant side effect 
when used in systemic chemotherapy.  Because of these toxicity issues and because of 
the potential of the drugs against a wide range of cancers, much work has gone into 
attempting to control this toxicity.  The toxicity can be manipulated through methods 
which center on specific targeting, such as intra-tumoral injection
111
 and polymer 
conjugation
112
.  The most successful of these manipulations, however, involve the 
liposomal encapsulation of doxorubicin, both pegylated
113
 (Caelix®) and unpegylated
114
 
(Doxil®).  This encapsulation not only limits the toxicity but also can increase drug 
penetration into the tumor
113
.  Regardless of the toxicity issues, this group of drugs is 





The group of anti-neoplastics, known as the anti-metabolites, contain some of the oldest 
and the newest drugs in the battle against cancer.  Methotrexate, in use since 1956
9
, spans 
many decades of drugs, from 5-fluorocil to recent purine analogs and conjugates.  
Despite the vast time frame, these drugs all act to disrupt the protein cascade involved in 
mitosis and thus prevent cell reproduction
121,122,123
.  The disruption of the normal cell 
cycle has allowed remission rates as high as 90%, in the case of methotrexate treatment 
against some cancers
124
.  The predominant issue with methotrexate lies in the associated 
virulent side effects
124
, an issue that the use of 5-flourocil was meant to address
123
.  The 
even newer, more effective and less toxic pemetrexed has already become a consistent 
choice for malignant pleural mesothelioma, a carcinoma of the lung tissue caused by 
asbestos
125
.   
 
Aside from the normal toxicity issues with chemotherapeutics, the anti-metabolites also 
suffer from short exposure to the tumor microenvironment due to low retention and high 
renal clearance
126
.  Thus, these drugs require metabolic rates above a minimum threshold 
to allow their mechanism of action to be effective, e.g. to halt the metabolic pathway
127
.  
To this end, much thought has been placed into entrenching the individual drugs into the 
target cells so they are not cleared from the environment
123
.  Interestingly, methotrexate 
and 5-flourocil have a synergistic effect on each other’s effectiveness, i.e. increasing 
retention and penetration, and are thus often used sequentially
128, 129
.  The anti-
metabolites are also often used in conjunction with other chemotherapeutics in 
combination therapy
130
.  Platinum-based drugs pair nicely with the anti-metabolites, as 
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their mechanisms of action are different enough so as to not conflict
131, 132
.  Also, folinic 
acid has worked well with anti-metabolites, alone and in combination therapy
132, 133
.  This 
success is theorized to be due to the catalyzing effect that folinic acid has on metabolism, 




Newer methods for enhancing the effectiveness of the anti-metabolites rely on 
encapsulation and the purine analogs.  Liposomal encapsulation and nanoparticle 
conjugation are means through which renal clearance can be lessened and targeting can 
be strengthened
126, 134
.  These methods hold much promise for this group, as their major 
issues lie in these areas.  Purine analogs attached to polymeric carriers also hold promise, 
as they can exhibit anti-metabolic activity, thus theoretically turning a polymer into a 
cancer fighting agent
135
.  These analogs attach to polymers, as well as other 
chemotherapeutics such as platinum-based drugs
136
, opening the door of the anti-
metabolites to many other modes of action. 
 
The platinum drugs also work in conjunction with another group of anti-neoplastics, the 
microtubule inhibitors. The microtubule inhibitors are a group of cytotoxic drugs, named 
for their mechanism of action, which inhibit mitosis through interference with the normal 
production/reduction of microtubules during metaphase
137, 138
.  The two main divisions of 
drugs in this group are the taxanes and the vinca alkaloids.  The commercially available 
taxanes are paclitaxel and docetaxel, which are among the most active chemotherapeutics 
against solid tumors
139
.  The taxanes were originally identified from portions of yew 
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trees, Taxus brevifolia and Taxus baccata respectively, but today most of the supply of 
drug is synthetic
140, 141
.  As the mechanism of action for the taxanes is rather unique 
amongst chemotherapeutics
142
, they are ideal for adjuvant therapy as the taxanes allows 
effective therapy against cells in a larger range of the cell cycle
139, 143,144
.   
 
The taxanes are not without drawbacks, however.  Taxanes have several systemic toxicity 
issues, including neural toxicity and hypertension
145
.   Also, paclitaxel has an extremely 
limited solubility in water
146
, making conventional release studies difficult
147
.  Also, due 
to the low water solubility, oil and emulsion vehicles are required for intravenous taxane 
administration to the body
148
.  The formulation for paclitaxel is traditionally Cremophor 
EL
®
, while the solubulizer for doxetaxol is usually polysorbate 80
141
, while other solvents 
and agents have been investigated
148
.  With these thoughts in mind, any type of localized 
delivery must be designed around these properties.  Devices such as coated stents, 
microspheres, surgical pastes, biodegradable implants, and liposomes have been 
investigated
149, 150
.  Prodrugs, such as isotaxel, have been investigated as well to boost 




The other, currently less popular, division of the microtubule inhibitors incorporates the 
vinca alkaloids.  Derived from the periwinkle plant Cantharanthus roseus, the first of 
these microtubule inhibitors was discovered in the 1950s
138, 152
.  This compound, 
vinblastine, was the first drug which used the principle of interfering with tubulin, 
symbolizing a shift in chemotherapy paradigm.  The release of vinblastine was followed 
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closely by the development of vincristine and, subsequently, vinorelbine and 
vinflunine
138
.  With each iteration, systemic toxicity was reduced while anti-tumor 
efficacy was increased
153
.  Vinflunine, developed in the early 2000s, is now used as a 
single agent therapy as well as in combination therapies against a wide range of solid and 
metastasized cancers
10
.  Chemically, the vinca alkaloids all share a common chemical 
structure with only slightly differing side chains.  This difference has led to much 
research into slight chemical modifications aimed at creating analogs of the alkaloids to 




Research into drug modification has paid dividends in the past, as is exhibited by the 
development of the topoisomerase inhibitors.  This family’s mechanism of action 
revolves around the inhibition of the enzymes DNA topoisomerase I and II
154, 155,156
.  
Through this inhibition, mitosis is disrupted, and tumor growth is retarded.  These 
antineoplastics are derived from the drug podophyllotoxin
157
 which has been used for 
hundreds of years as a folk medicine but for which the anti-mitotic properties were 
discovered within the past century
154
.  While podophyllotoxin proved to create 
unacceptable toxic side effects, development work led to the discovery of the semi-
synthetic derivative etoposide in the 1950s.   
 
Etoposide is still known to be a highly toxic drug, causing myelosuppression and 
mucositis
158
.  Due to the high efficacy and the long period of history of development, 
much work has gone into quantifying the therapeutic window of etoposide
159
.  Data 
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indicates that antitumor activity begins as low as 0.5 ul/mL, and treatment can be 
tolerated in a dose as high as 10 ug/ml
160
.  This, still imprecise, quantification of the 
therapeutic window is rare to find amongst chemotherapeutics and could eventually lead 
to more effective treatment options for patients as more work is continuing on the topic. 
 
This therapeutic window work has also led to further quantification of etoposide 
properties which allow more unique usages of etoposide.  For example, thermal 
characterization has been executed on etoposide and many of its derivatives
161
, allowing 
further processing of the drug.  Also, much microbiological analysis has proven capable 
of identifying protein binding sites and methodology
162
.  The ability to process the drug 
at temperatures up to 300°C, along with the advanced elucidation of metabolic pathways, 
allows novel formulation and administration such as phosphate prodrug forms
163
, but 
perhaps more importantly as an oral form
164
.  The oral form allows the use of outpatient 
chemotherapy, which has been shown to be on par in terms of tumor response with in 
hospital intravenous administration. 
 
While etoposide works through inhibition of DNA topoisomerase II, two other drugs, 
topotecan and irinotecan, work through inhibition of DNA topoisomerase I
155, 156
.  These 
drugs were developed as analogs of camptothecin, in a similar manner as etoposide was 
an analog developed from podophyllotoxin.  Topotecan is administered as a single agent 
and in combination therapies quite effectively due to the synergistic activity it exhibits 
with other antineoplastics such as the platinum drugs
165
.  Also, the lipophilic nature of the 
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drug allows it to cross the blood brain barrier easily, aiding in treating more dangerous 
cancers such as that of the brain and spine
166
.  It is not, however, immune to the side 
effects that plague etoposide, being quite toxic to the nervous system
167
.  Attempts to 
limit this toxicity and increase the water solubility of the drug center around nano-




The other type II inhibitor, irinotecan, has become a frontline, single agent treatment for 
colorectal cancer
170, 171
.  This water soluble topoisomerase inhibitor follows a very 
complex metabolic pathway to the form of its active metabolite SN-38
172
.  However, this 
metabolite is more toxic in some patients than are the other topoisomerase inhibitors
173
.  
The reasons for this difference between patient groups have yet to be fully investigated, 
however data collected is beginning to reveal clues
174
.  Further investigation will allow 
more accurate use of this effective drug.  
 
Another drug of which not much is known is altretamine.  The mechanism of action for 
this drug has yet to be fully understood, however chemically it resembles members of the 
alkylating agents
175
.  This antineoplastic requires metabolic activation for its cytotoxic 
effects to be activated
176
.  Because of this requirement, altretamine is administered orally 
so as to take greatest advantage of its properties
177
.  Altretamine does not have high 
success rates (10-20%) and so is often administered as a salvage therapy drug, a “drug of 
last reasort”
178
, in malignant metastasized cancers such as ovarian which have proven 
resistant to other more traditional treatments
179
.  The side-effects associated with 
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Non-cytotoxic drugs have also found their way into the fight against cancer.  Certain 
cancers, such as that of the breast, are resistant to cytotoxic chemotherapy but respond to 
other types of regimens.  One such regimen involves the deprivation of certain hormones, 
such as estrogen or androgens, in order to “starve” hormone-resistant tumors.  The 
majority of work in alternate regimens of this type has manifested itself in breast cancer 
research, where up to approximately two-thirds of tumors are hormone-resistant
181
.  This 
research has produced two types of drugs, aromatase inhibitors (AI) and selective 
estrogen receptor modulators (SERM), which are designed to slow growth of such 
cancers.  Both of these drugs have applications, such as ovulation induction and 
endometriosis treatment, outside tumor treatments, 
182,183,184
.  SERMs such as raloxifene 
have been investigated in tumor regression, but tend to be overshadowed by the 
aromatase inhibitors. 
 
The aromatase inhibitors, for the quarter century prior to 2000, were dominated by 
tamoxifen
181
.  Tamoxifen was developed quickly on the heels of the first AI, 
aminoglutethimide, and greatly increased the efficacy of the class of drug
185
.  Tamoxifen 
and other AIs inhibit the enzyme aromatase, which is the key enzyme in estrogen 
biosynthesis
186
.  Breast cancer is highly dependent on estrogen for sustenance and 
replication.  Thus, with use of AIs such as tamoxifen, breast cancer can be forced into 
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remission in a wide range of cases
187
.  In the past decade, two new AIs have come to 
light.  Anastrozole and letrozole, the third generation of AIs, have been shown in multiple 
studies to be more effective than tamoxifen in combating growth of breast tumors
188-191
.  
One such study even shows that letrozole can inhibit more than 99% production of 
estrogen
192
.  The ability to administer anastrozole orally makes the drug even more 
attractive
193
.  While shown to be effective in treatment of male breast cancer
194
, hormone 
treatment has been shown to be potentially damaging to quality of life of premenopausal 
women post treatment.  For this reason, AIs are usually used in postmenopausal women 
and men. The potential of drugs such as these should not be overlooked, as the ability to 
treat cancer without cytotoxic drugs is one way of limiting the well-documented and 
generally distasteful side effects of chemotherapy. 
 
Continuing with the theme of non-cytotoxic drugs for the treatment of cancer leads to the 
anti-angiogenesis agents.  These drugs attempt to combat tumor growth through an 
indirect route, by depriving them of the vasculature necessary to grow, rather than by 
inducing apoptosis.  This inhibition is possible because cancers have been observed to be 
incapable of growing beyond two millimeters in size without the production of a stable 
vasculature
195
.  With this in mind, bevacizumab was developed and first approved by the 
United States Food and Drug Administration (US FDA) in 2004
196
.  Bevacizumab is a 
human monoclonal antibody which targets vascular endothelial growth factor (VEGF), a 
factor which is largely responsible for the production of vascularization in the human 
body
197
.  VEGF is often over expressed in cancerous growths, as the goal of such growths 
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is to replicate as quickly as possible; thus, combating the expression of this growth factor 
can slow tumor progression
198
.  Preventing the angiogenic shift from unvascularized 2-3 
mm tumors to vascularized, metastasizing cancer can be critical to combating such a 
growth, but action to stop such a progression must be taken early
199
.  As early detection 
abilities improve and increase the number of tumors which can be made visible, drugs 
which can retard angiogenic growth and maintain tumors at manageable sizes will 
become more and more valuable.  Further, the various other effects of bevacizumab, such 
as regeneration of normal vasculature and tumor oxygenation, occur in concert with the 
effects of cytotoxic drugs, thus making bevacizumab ideal for adjuvant/combination 
therapies
200, 201
.  Furthermore, bevacizumab is well tolerated
202, 203
 and associated with 
only mild or treatable side effects.  The drug is even inexpensive as compared to other 
chemotherapies
204
.  However, despite all these positive attributes, bevacizumab is still 
only truly effective in combating very early stage tumors.  Anti-angiogenic research does 
hold promise for future success in the clinic. 
 
The other big name in the field of anti-angiogenesis is an old one, soiled through a 
textbook example of poor pre-market testing.  Thalidomide is a glutamic acid derivative 
which was first synthesized in 1954
205
.  The drug was immediately noted for being so 
non-toxic that a lethal dose causing death of half an animal test group (LD50) could not be 
established and the fast acting relief of myriad symptoms, including morning sickness
206
.  
The drug was marketed over the next decade as a non-barbituate sedative, especially 
popularly prescribed to pregnant women.  However, thalidomide proved to be tetragenic 
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and over 10,000 babies were born with severe debilitating birth defects prior to the 
discontinuation of the drug’s usage.   From this negative story comes a silver lining of 
good news, as thalidomide was not completely abandoned from research laboratories.  
Over the next fifty years, a range of uses for the drug have been developed.  Most 
importantly to the oncologic community, it has been shown to be anti-angiogenic in 
nature
207
.  This characteristic, coupled with low toxicity, has led to experimental use 
against a wide range of solid tumors
208
, and even FDA approval for cancers such as 
multiple myeloma
209
.  While being administered exclusively through oral tablets
210
, the 
mechanism of action for thalidomide has yet to be elucidated fully, even after decades of 
study
211
.  What is known is that thalidomide is composed of a racemic mixture of two 
enantio-isomers, which racemize rapidly under physiological conditions
212
.  This 
attributes to the speedy effect of the drug, as well as the masked tetragenic effects, as 
only one of the isomers is tetragenic and only in the racemized form.  Also, the drug is 
rapidly broken down in the body, with a half-life of only 4-5 hours.  This point explains 
the almost negligible toxicity of the drug, as chemical build-up in tissues and organs is 
almost impossible on this short timeframe.  All of these properties make thalidomide an 
attractive choice for non-cytotoxic chemotherapy.  However, concerns raised by the 
thalidomide failure half a century ago, must still be addressed before this drug will 





Tumor Microenvironment and Growth 
After reviewing the major players in the field of chemotherapy today, the next logical 
step is to examine the target for the drugs, i.e. the tumor and associated metastasis.  
Clinically, much work has been performed, using tumor size reduction and associated 
progression-free survival rates as the metrics by which cancer treatment “success” is 
determined.  While these metrics are the quantitative measurements with which treatment 
should be concerned, research must keep in mind the reasons for this success as this line 
of inquiry will inform new approaches and directions.  Description and visualization of 
the tumor microenvironment has taken a back seat to drug development and mechanism 
elucidation in the past twenty years.  Luckily however, researchers are beginning to direct 
more attention to the how and why of cancer development, angiogenesis and growth.  
This knowledge will allow more successful treatment of carcinomas in the long run, 
ultimately boosting the most important metric, survival. 
 
The first and most important item of note when examining the tumor microenvironment 
is the diversity of the area.  Human neoplasms contain a plethora of differentiating cells 
in terms of function
213
.  From this variation comes perhaps the most important facet of 
knowledge related to the tumor microenvironment, that tumors exhibit heterogeneity in 
terms of cell type
214
.  While one school of thought advances that tumors originate from a 
single, malformed cell, tumor cell differentiation occurs early in the growth process.  This 
process leads to a series of concurrent factors which either inhibit or encourage growth
215
.  
The carcinoma grows outward, through stromal cells on the leading edge of the tumor.  
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These cells in turn interact with the surrounding extracellular matrix (ECM).  The 
complicated interactions between these fronts of cells are often the largest indicator of 
either growth or stagnation of the tumor.  Dr. Stephen Paget was the first to put forward 
the “seed and soil” analogy
216
, in which he compared a neoplasm to that of a seed and the 
surrounding ECM to the soil.  By controlling the soil he postulated, one could retard the 
growth of a seed.  As any farmer knows, it is easier to salt the ground than explant a 
series of seeds. 
 
This analogy leads easily to the question of how the cancerous “soil” differs from normal 
tissue.  Studies have been performed to answer this question and have identified 
numerous differences between cancerous and non-cancerous cells
216
.  Cancerous tissue 
often exhibits low levels of pH as well as glucose, which is attributed to the rapid 
replication of cells, indicative of a tumor.  Also, hypoxic conditions are almost 
universally present at tumor sites.  The hypoxia is due to the lack of a comprehensive 
vasculature; the lack of oxygen contributes to the large number of mutations seen in 
malignant tumors due to the disrupted replication of DNA.  Also, tumor tissue exhibits 
high levels of necrosis as cells struggle to survive in the hazardous conditions described.  
Ironically, necrosis of cells at the core of solid tumors has been postulated
216
 to actually 
catalyze outward growth of the tumor as macromolecules and nutrients are released 




This process explains why the core of the tumor differs greatly from the outer palisade 
cells
217
.  This point is also highlighted by the difference in interstitial fluid pressure (IFP) 
in the tumor.  Due to the poorly vascularized nature of the core of the tumor, caused by 
the vascular irregularities inherent in tumors, IFP rises.  The rise in IFP, coupled with the 
generally porous or “leaky” nature of tumor vasculature,
218
 makes drug delivery via 
normal routes e.g. blood pathways, very difficult.  Also, the cells in the outer region of 
the tumor, close to the blood vessels have a higher rate of proliferation than those found 
in the necrotic core
219
.  The increased cell density in the outer region makes penetration 
deep into the tumor very difficult.  Finally, the last major difference between healthy and 
cancerous tissue can be seen in the difference in temperature.  Temperatures in cancerous 
tissue can rise as high as 113°F (45°C)
 219
.  This excess energy can be used to catalyze 
intracellular processes and thus speed processes such as metabolism and mitosis. 
 
These differences in microenvironment amount to a double edged sword.  On one hand, 
properties such as rise in temperature provide the ability to target cancerous tissue 
specifically using technologies such as temperature-sensitive polymers.  Conversely, the 
tumor microenvironment can present one of the largest obstacles to chemotherapy in the 
form of drug resistance.  Drug resistance can be developed through mutations of cells 
surviving treatment (occurring rapidly and spontaneously due to the hypoxic conditions) 
or can reside inherently in the tumor prior to exposure (de novo resistance)
 220
.  An 
example of such resistance can be seen in the production of excess glutathione in tumor 




.  Tumor chemoresistance is the leading cause of failure of 
chemotherapy, because even if a small portion of the heterogenic tumor is resistant to a 




The investigation and visualization of the tumor microenvironment is an area of ongoing 
work in the realm of oncology.  Probes such as fluorescent nanoparticles and quantum 
dots have been used to visualize tumor structures and vasculature
215
.  Tissue preparation 
and immunohistochemical staining allow post-excision analysis.  Immunhistochemistry is 
often used to determine the microvessel density of a tumor, which is directly related to 
angiogenesis
222
.  This assessment becomes necessary as the quantification of 
angiogenesis is essential in determining the stage of the tumor and propensity to 
metastasize
223
.  In general, the more vascularized the tumor the more advanced the 
growth and hence the more danger to the host
224
.  Thus, visualization of the cells is 
important and allows further investigation of solid tumors.  This heterogeneity of tumors 
and the surrounding microenvironment, once studied and fully understood, may provide a 




A better understanding of the microenvironment will, in turn, lead to a better 
understanding of the mechanisms by which tumors grow and better methods through 
which to model tumor growth.  Such models are important in tailoring treatments to 
patients and predicting efficacy of such treatments.  The mainstream of thinking for a 
long period, prior to the turn of the century, was that every carcinoma was inherently 
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different and there was little possibility of predicting the growth of such a tumor through 
a universal mathematical model.  However, in 2001, it was shown that tumors throughout 
nature follow a same general exponential curve
226
.  While simplistic (growth slows as it 
reaches a limiting factor), this statement describes that cancer cells react as a population, 
meaning that growth is not completely unchecked.  This concept of tumor growth relates 
directly with the discussion previously on tumor microenvironment, and raises the 
interesting question of how medicine might force the retardation of growth sooner. 
 
Development of mathematical models not only highlight questions such as how tumor 
growth can be examined but allow the elucidation of better treatment regimens by 
identifying key parameters, such as tumor size, vascularity location etc.  This is achieved 
first, much like any other mathematical model, by defining the relevant variables.  Items 
such as cell structure, environmental factors, adhesion between cells and rate of 
proliferation are often common across different proposed models
227
.  Behind these 
obvious variables are, however, the complex interactions which one must quantify.  For 
example, as a tumor grows into the surrounding ECM, the ECM structure is damaged and 
broken.  During this destruction, nutrients and growth factors such as VEGF are 
released
228
 which can then be used by the advancing stromal cells.  Therefore, it can be 
easily argued that this advancement catalyzes itself through a positive feedback loop.  
The growth, along with the VEGF, will induce angiogenesis which will further speed 
tumor growth.  Hence, mathematical models can be useful in the identification of an 
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acceleration point for tumor growth and therefore can be useful in the determination of 




Tumor growth presents a problem to simple modeling because growth is a dual-stage 
process
230
.  The first stage is that of pre-vascularization.  Here, the tumor grows to the 
size to which it is limited by the limited capacity to provide nutrients to the core via in the 
absence of a vascular network.  In this stage, a tumor can grow no larger than 
approximately 2 millimeters.  However, with angiogenesis and the ability to supply 
necessary elements to other regions, growth commences again.  The second stage 
progresses until metastasis occurs, at which point modeling becomes unwieldy and less 
relevant.  Thus any model must represent the growth as a dual compartment model
231
.  
Therefore, the models can be described in terms of two stages, as outlined by Sachs
231
; 
the first stage of tumor growth can be presented as such: 
 
N is the number of clonogenic cells and λ is a constant
231
.  This simple exponential 
growth equation is adequate for modeling the first stage; however, upon angiogenesis, 
two equations are needed.  The first equation represents the tumor core: 
 
K is a carrying capacity determined by the second compartment volume.  The second 
equation is related to the speed at which vascularization occurs, the depth at which it 
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occurs and speed of replication resulting from such nutrient availability.  These 
characteristics are represented by the general form: 
 
D is the depth of penetration, S is the speed of penetration, V is the volume of the tumor 
at time 0, and ρ is the density of cells in the tumor at time 0.  This simplified model is 
meant to describe the potential for the tumor to grow to a carrying capacity K, which is in 
turn defined by the level of angiogenesis, as time progresses.  This mathematical 
description again correlates to the idea of quantification of the stage of cancer relating to 
that of the level of vascularization of the tumor.   
 
This proposed model can obviously be improved through the inclusion of further 
variables or the use of further compartments which have been proposed to represent 
“shells” or areas of differing tumor growth
232
.  The example model proposed is intended 












TUMOR TREATMENT IN MODERN MEDICINE 
 
Tumor Treatment and Administration Methods 
The information provided to this point describes two of the tools required to treat cancer 
using chemotherapy.  The first tool, the drugs themselves, is specific to a method, 
whether it be deoxyribonucleic acid (DNA) intercalation, anti-angiogenesis, or any other 
mechanism.  The second tool, knowledge of the physiology of tumors, guides the 
selection of the drug.  The missing tool is the method of drug administration to the tumor.  
Modern chemotherapy administration comes in many different forms, the exact 
mechanism is usually indicated by the location and stage of the cancer. 
 
Intravenous (IV) chemotherapy was first used in 1942 at Yale University
233
.  Following 
this initial success, IV chemotherapy became the gold standard against which other 
chemotherapy regimens were judged.  IV chemotherapy seems logical at first glance; it is 
easy to administer, compatible with most hydrophilic chemotherapy agents, poses a low 
risk of infection, and exhibits a high rate of efficacy.  This route of administration relies 
on the circulatory system to route the drug through the entire body, exposing areas other 
than the target tumor to the cytotoxic drug.  However, recent studies have shown that, for 
some solid tumors, intraperitoneal (IP) administration is as effective or even more 
effective than a similar concentration administered through IV
234, 235
.  IP administration 
has been shown to be more cost effective in terms of cost versus survival-free 
progression, making it an interesting economic choice
236
.  Other studies have even 
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examined using the two together, to great effect
237
.  The one drawback of IP 
administration appears to be slight toxicity to the injection site, as one would expect from 




Oral chemotherapy presents the most patient-compliant form of chemotherapy.  Patients 
are often more inclined to take a pill than undergo injections or infusions, and oral 
chemotherapy does not require a visit to the physician’s office.  However, only certain 
drugs are capable of oral administration while others require modification, such as 
encapsulation
239
.  Even so, oral administration has been found wanting in terms of tumor 
response when compared to standard IV administration
240
.  For this reason, oral 
chemotherapy is often only used in cases where previous evidence assures success, or 
when other methods have failed. 
 
The newest iteration of administration is that of intratumoral (IT) injections.  This method 
consists of injecting the chemotherapy directly into the tumor.  This has the advantages of 
completely perfusing the tumor (allowing access of the drug to the poorly vascularized 
core) and maximizing the drug concentration at the desired site.  This method has already 
been shown to be more effective than IV treatment in some cases, with reduced toxicity 
allowing treatments of children and the elderly
241
.  The reduced toxicity is attributed to 
the lack of “collateral damage” as the cytotoxic drugs do not penetrate any tissues other 
than the target and have perhaps very slight diffusion into the surrounding cells
242
.  
However, the largest obstacles to the acceptance of IT treatment stems from conservative 
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physicians and the need for a clear, accessible tumor.  Surgical removal often does not 
leave a visible target and so IT treatment is currently regarded as a “pre-operative” 
modality. 
 
After determining how to administer chemotherapy, one must determine the timing.  
Traditionally, chemotherapy is administered in high, concentrated doses with weeks in 
between to allow the body to recover
243
.  This “cool-down” period is necessary when 
such high levels of drug are introduced because build-up of the cytotoxic drug not only 
occurs at the tumor site, but also in collateral, healthy tissue.  Because of this necessary 
break in treatment, tumor cells have a chance to replicate and, worse, develop drug 
resistance mechanisms.  Therefore it is imperative to find ways of administering 
chemotherapy on a more frequent basis.  This can be done through simple modification 
of dosing schemes, such as through metronomic or dose-dense scheduling. 
 
The goal of metronomic scheduling is to expose the tumor to a constant, frequent, low 
level of drug
244
.  Because of the low levels of drug administered, cytotoxic side effects 
are seen less frequently, as the body is more capable of clearing the drug not absorbed 
into the tumor and preventing the build-up of the drug in “healthy” tissue.  Also, by 
constantly exposing the cancerous growth to a given cytotoxic drug, the tumor has no 
chance to regrow and has much less time in which to develop a drug resistance.  Thus, 
since most cytotoxic drugs attempt to interrupt cell division at a certain stage, it stands to 
reason that it is essential that all the tumor cells be exposed to the drug while passing 
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through that stage of the cell cycle.  A sound idea in practice, low dose metronomic 





, and anti-angiogenic factors
247
.  Even more interesting, tumors that 
develop resistance to LDM have been shown to still be sensitive to higher doses of drugs, 




The main difficulty with LDM is a poorly defined lower threshold for the therapeutic 
window for most chemotherapeutics.  That is, it is not clear at what level one can 
administer the desired drug and still maintain efficacy.  Dose-dense (DD) chemotherapy 
evades that question, and encompasses a more constant schedule.  The goal of DD is to 
maintain a constant, high level of drug at the site of the tumor.  This delivery is executed 
in a similar manner as metronomic scheduling, with higher concentrated doses than LDM 
but lower doses than traditional means.  Thus, by continually replenishing the drug 
concentration at the tumor site, better clinical results should follow.  Success with this 
treatment process has been seen with multiple paclitaxel/platinum
62, 63
 and other 
combination regimens
248
.  The greatest problem with dose-dense chemotherapy is the 
increased toxicity associated with the more frequent treatment administration.  However, 
even this problem has been shown to be controllable through conscientious dose choice
61
.  
Thus, DD chemotherapy is becoming a more attractive option in hospitals and clinics 
around the world. 
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Biomaterials are increasingly playing a role in aiding the administration of 
chemotherapeutics, and are being used as in situ delivery systems, microparticles, and 
polymeric conjugates.  A chemotherapeutic is often administered in a form other than a 
free drug in an IV solution.  The best example is a diluent such as BASF’s Cremophor 
EL®.  This excipient, which is simply a reaction of ethylene oxide and Castrol oil, is 
used to solubilize the hydrophobic drug paclitaxel.  This allows the administration of 
paclitaxel through IV means into the circulatory system without massive precipitation of 
the solute.  The problem with such a system lies in the side effects elicited by the 
inclusion of Cremophor EL, which are highlighted by hypertension.  With the already 
high level of harmful side effects seen in the use of chemotherapeutics, one can 
understand why any further toxicity caused by additional components would be 
undesirable. 
 
Not all delivery aids are solubilizers and excipients.  Pluronic® copolymers have been 
shown to interact with tumors, independent of drug presence
249
.  The presence of these 
polymers at the tumor site has been shown to sensitize normally drug-resistant tumors.  
The mechanism of action for this sensitization is proposed to be the adenosine 
triphosphate depletion induced by the presence of the polymers, thus weakening the 
cancerous cells defense mechanisms.  Hence the administration of these polymer 
solutions concurrently with chemotherapeutics has shown promise in overcoming of 





Polymers are valuable to chemotherapy as liquid carriers and polymer drug conjugates 
are playing an increased role in therapies as well.  Because the majority of the drug’s 
target resides within the cell, usually either DNA or microtubules, transport and uptake to 
the cytoplasm is a key component of cancer therapy.  Initially, viral vectors were 
attempted to facilitate such transport.  However, problems were seen with toxicity and 
immunogenicity
250
 and so non-viral methods were explored.  This led to research 
involving cationic polymers.  Cationic polymers allow the conjugation of many different 
anti-neoplastic drugs.  These conjugates exhibit better biocompatibility, circulation time 
and drug uptake within cancerous cells, while inflicting lower systemic cytotoxicity
250
.  
Cationic polymers rely on the cell substructure to cleave the polymer from the drug, 
hence catalyzing the prodrug to drug transition in situ. 
 
Polymers are also tailored to be environment sensitive to release their drug payload.  
Polymer drug conjugates have been designed both with pH and temperature sensitive 
linkages.  Polymers conjugated to drug through acid-sensitive linkages are capable of 
circulating through the body multiple times until the cancer site is reached.  Acidic pH is 
indicative of a tumor site and so the polymer-drug conjugate will preferentially separate 
at the tumor site
251
, thus allowing targeted delivery to the tumor microenvironment.  
Temperature-sensitive polymers are capable of working in the same manner, though the 
polymer-drug linkage is less likely to be a strict covalent bond and more likely a sol-gel 
network
252
.  These examples are just a few of the ways that the tumor microenvironment 
can be targeted by polymeric conjugates.   
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Through the use of polymeric linkages, delivery mediators can also be attached.  Binding 
the drug to a polymeric scaffold creates other sites for attachment.  These sites can be 
used to bind targeting moieties, such as folic acid.  Folic acid constitutes an interesting 
choice for a targeting element as it is easy to attach, upregulated in many tumors, 
overexpressed in relation to size and grade of tumors, and normal tissues shield the 
majority of their folate receptors
253
.  Thus the complex will be preferentially incorporated 
by cancerous cells and will release the drug from the prodrug complex within the desired 
cells. 
Polymeric conjugates are not the only option for 
facilitated delivery to cancer cells.  Liposomes 
(Figure 2.1) also offer a significant advantage over 
free drug administration.  Liposomes consist of a 
lipid bilayer surrounding an inner cavity which, 
through special processes such as water-in-oil-
water emulsion preparation, can be made to 
encapsulate drug
254
.  These liposomes then freely 
circulate the body for extended periods of time, due to their relatively bioinert 
characteristics, until they settle into tissue.  The “leaky” vasculature of cancer tissue 
allows the preferential deposition of liposomes at the tumor site.  However, once in place, 
the stable liposomes are not inclined to self-degrade and release the encapsulated drug.  
Many mechanisms, such as phototriggering, have been investigated to allow the in situ 
release of drug from liposomes
255
.  
Figure 2.1: Example 
configuration of a liposome 
(Source:  www.thescientist.com) 
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As their name implies, liposomes are inherently hydrophobic, at least to a slight degree.  
While useful for applications such as traversing the blood brain barrier, this characteristic 
is detrimental in general systemic delivery.  For this reason, liposomes can be surface 
modified using a process described as PEGylation
256
.  This process entails the attachment 
of the biocompatible and hydrophilic polymer polyethylene glycol (PEG) to a given 
structure to increase the overall hydrophilic and biocompatible nature of the entire 
complex.  The process, first described in the 1970’s, allows the attachment of PEG to a 
bioactive molecule through various mechanisms such as acylation or methylation, etc.
257
.  
This molecule does not have to be a polymeric complex, but can be a protein, peptide or, 
even for chemotherapeutic applications, a hydrophobic anti-neoplastic drug. 
 
Further work in the field revolves around the use of nanoparticles and microspheres.  The 
aim of such work is similar to that of liposomal delivery, but attempts have been made to 
use less lipophilic carriers.  These carriers generally take the form of nanoparticles or 
microspheres.  These small particles can be prepared from a variety of materials, 
polymeric and non-polymeric.  Nanoparticles prepared from biodegradable polymers 
such as polylactide-co-glycolide (PLG) are gaining favor currently as PLG has a low risk 
of a toxicologic or immunogenic response.  These items can be prepared for drug 
delivery and diagnostic uses for cancer therapy
258
.  Nanoparticles will also preferentially 
seek out the ‘leaky’ vasculature of tumors, much like liposomes.  The leaky vasculature 
provides an almost sieve-like system, leading to the surrounding tumor, in which a 
properly sized nanoparticle will deposit
259
.  Equally important to the retention of 
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nanoparticles in the tumor is the poor drainage of the vasculature relative to normal 
tissue.  These two factors combine to allow a majority of the administered nanoparticles 
to eventually target the tissue.  The collection of fluorescent nanoparticles in the tissue 
can allow non-invasive visualization of neoplasms. 
 
Nanoparticles and microspheres have already begun to show their worth in terms of drug 
delivery.  Studies as early as 1996 showed that microspheres containing methotrexate 
elicited a better clinical response to treatment than free methotrexate
260
.  Anti-angiogenic 
delivery is quite popular and effective due to the area of effect
261
.  Nanoparticles have 
even found use in treating cancers of the central nervous system, where other methods are 
only effective over a limited area
262
.  Nanoparticles have also been shown to aid in 
sensitizing tumors which were otherwise resistant to their payload drug, much like the 
Pluronic® polymers
263
.  Work has also been conducted using microspheres as 
placeholders for ligands, thus creating actively targeted therapies.  These properties, 
along with the ability to incorporate most drugs used in chemotherapy in a 





While nanoparticles show promise in targeted therapy, the next step is localized delivery.  
The advantages of localized delivery over normal systemic treatments include lower 
systemic toxicity, more efficient usage of the drug, and better treatment outcomes.  The 
difficulty in this field is the ability to deliver a suitable delivery vehicle to the site of 
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treatment.  Medical devices such as implantable chemotherapeutic wafers for brain 
cancer have been tried with little success.  However, devices which do show promise for 
localized delivery are injectable in situ forming implants. 
 
These implants begin the treatment cycle in a solution (sol) form.  This solution is then 
administered to the desired area of treatment through a syringe or port system.  Once in 
place, or in situ, the implant then converts to the gel form.  This transition is often called 
the sol-gel transition and the mechanism through which this change is effected is one of 
the distinguishing factors between systems.  The majority of injectable in situ-forming 
systems fall into one of three categories: (1) crosslinking/network formers, (2) 




The first group of such systems relies on the difference of the environment at the site to 
induce cross-linking and thus the development of the desired construct.  This difference 
can either be an inherent physiochemical difference or an induced change.  Examples of 
induced changes include ultraviolet irradiation, temperature and pH modification
268
.  
Once cross-linking is induced, networks are formed between chains (usually polymeric).  
These networks then release their pharmaceutical payload in a controlled manner
269
.  The 
release of such molecules can be modulated by the level of cross-linking, the polymer 
scaffold employed, and the method of cross-linking
270
.  The most popular polymer 
matrices in this area are those of the pH-responsive type, often using the biocompatible 
natural polymer chitosan
268
.  These in situ implants are capable of being delivered 
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through physiological pH (7.4), remaining in the sol state, to weakly acidic (pH 6.8) 
environments where the sol-gel transition occurs
271
.  In this manner, the transition to a 
“delivery state” can be contained to a pH usually located only in tumor sites.  While 
effective, these types of treatments do have drawbacks.  Cancer pH values are not 
constant across tumors or even within a particular tumor.  Also, once formed, hydrogels 
produced through sol-gel transition tend to be weaker physically then other methods, 
making stability an issue
272
.  These drawbacks are significant, and much current work is 
being geared toward overcoming these obstacles.   
 
More popular among researchers are the 
thermogelling in situ forming systems.  
These systems are activated by elevated 
temperatures and are characterized by their 
lower and upper critical solution 
temperatures (LCST and UCST).  The 
commercially available family of Pluronic® 
polymers is the best known example of such 
a system
273
.  These polymers are poly(ethylene oxide) and poly(propylene oxide) block 
copolymers which allow the thermocontrolled construction of controlled delivery 
implants by engineering the UCST to be between room temperature (~20ºC) and body 
temperature (37ºC).  When implants from polymers such as those described have been 
formed in situ, controlled release of multiple chemotherapeutics has been exhibited
274,275
.  




Systems engineered using polymers such as elastin-like polypeptides can even be 
designed to deliver multiple drugs at different temperatures by creating regions with 
different CSTs
276
.  The flexibility of such systems is attractive to researchers, but the 
reliance on physiologically fluctuating temperature again poses a hindrance to 
widespread use. 
 
The final group of in situ-forming implants is perhaps the most complicated, yet 
intriguing, group.  This group relies on the self-assembly of implants once introduced to 
the site.  This reliance on mechanisms other than cross-linking, pH, or temperature makes 
systems such as these more difficult to prepare but more useful once in place.  These 
systems often rely on precipitation and phase-separations to elicit the desired construct.  
Collagen gels have been shown to be capable of intratumoral delivery using such an 
approach
277
.  Other materials involved in systems using methods such as these include 
novel tissue adhesives
278
 and hyperbranched hydrogels
279
 which are designed to be 
physically more stable and therefore more effective drug delivery systems than those that 
rely on external stimuli to induce the sol-gel transition.    
 
Extension – What Next? 
The obvious question for one to ask is “what next”?  A significant base of work has been 
put into understanding chemotherapy.  The drugs with which chemotherapy is performed 
are well documented.  Current understanding of the tumor microenvironment and kinetics 
of growth are becoming better understood at a rapid pace with today’s technology.  
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Delivery routes other than traditional IV administration are becoming more common and 
accepted.  Chemotherapy has the potential to become a much more prominent player 
in the war on cancer.  Through more effective usage and administration of common 
chemotherapeutics, chemotherapy can be made into a more acceptable treatment for 
cancer patients.  The goal of such optimization should revolve around limiting side 
effects and increasing the efficiency of such treatment. 
 
Ovarian cancer is a known chemoresponsive malady.  Treatment of this disease 
commonly focuses around usage of paclitaxel and platinum-based drugs administered 
intravenously in combination therapy.  This treatment regimen has been shown to aid in 
the regression of tumors following surgical debridement.  This treatment is not, however, 
without drawbacks; systemic IV administration leads to full-body toxicity and a slew of 
undesired side effects.  Also, drug is inefficiently delivered to the tumor, and even less 
reaches the intracellular environment where anti-neoplastic activity can occur. 
 
Furthermore, this uncontrolled delivery to the tumor site causes the discarding of the 
traditional clinical tool, the therapeutic window.  The therapeutic window is often defined 
as the concentrations of a bioactive agent above the lowest efficacious dose but below the 
maximum tolerated dose.  Work such as the development of dose dense and metronomic 
scheduling has contributed greatly to allow controlled drug levels, but still does not 
account for a truly controllable drug concentration.  Also, each time agents are 
administered, excipients such as Cremophor EL® are required for treatment.  These 
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agents themselves have been shown to elicit harmful side effects when administered 
systemically.  The administration of controlled delivery vehicles also must ensure the 
biocompatible nature of the device, and the eventual need for clearance or removal from 
the body. 
 
Treatment must be optimized; this optimization can take the form of an in situ- forming, 
biocompatible construct.  The injectable nature and self assembly of such a device allows 
localized delivery of chemotherapeutics.  Administered intratumorally, such an implant 
will remove many of the issues resulting from systemic administration of drugs.  Also, 
through the use of a biocompatible, absorbable system, safety can be increased and 
explantation will never be required.   
 
Lastly, through the controlled diffusive release of encapsulated drugs, such as paclitaxel 
and carboplatin, treatments can be optimized to provide constant levels of drug.  Dose 
dense and metronomic dosing schemes have already shown that lower levels of drug 
administered more often can be effective.  It therefore stands to reason that a constant 
delivery of low levels of drug in situ could be even more effective, again limiting 
systemic toxicity. 
 
With all of these factors considered, an injectable in situ forming implant is therefore 
proposed.  This implant should be biocompatible and capable of controlled release of 
chemotherapeutics.  By using cancer of the ovaries as a model, an effective system could 
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be developed.  Once proven, the developed system could in turn act as a model for 
development of other treatments for chemosensitive cancers at other sites in the body.  
Using new polymeric systems, this treatment could open up new, safer, and more 






















THE OC SYSTEM: A METHOD FOR LOCALIZED SUSTAINED DELIVERY  
Overview 
As noted in the previous chapter, there is currently a dearth of technology specifically 
engineered to encompass both local and sustained delivery.  If such a candidate could be 
designed and prepared, a significant step in the war on cancer would be achieved.  One 
such delivery system being developed is the OC system (Poly-Med, Inc., Anderson, SC).  
This platform technology comprises an injectable in situ forming drug delivery depot that 
does not rely on fluctuating environmental factors to induce the sol-gel transition.  
Rather, the mechanism of formation is simply exposure of the formulation to an aqueous 
environment.  The injectable solution is composed of several components.  The OC 
polymer forms the actual depot delivery system.  OC polymers are a block copolymer 
design with both hydrophobic and hydrophilic segments.  In order to facilitate the 
injection of the system, a polymeric diluent is used.  If necessary to further modulate 
release, polymeric additives are introduced which control the structure of the delivery 
construct and construct drug interactions.  The final component of such a system is the 
bioactive agent, such as carboplatin, which is used for delivery.  This system is a 
homogenous solution prior to introduction into a biological environment. Upon injection 
into the desired site, a drug delivery depot forms rapidly (Figure 3.1).  
 
This depot formation occurs when the water-miscible polymeric diluent evacuates the 
solution, allowing the remaining solutes to coalesce.  Following this theory, the OC 
 49 
polymer orients itself into a thermodynamically favorable conformation, resulting in a 
stable polymeric construct.  The uniqueness of this formation in relation to other hydroset 
gels is exhibited by the hydrophobic and hydrophilic differences throughout the polymer 
chain.  This property difference, inherent in the polymer chain itself, helps drive the 
orientation of the delivery depot to a repeatable, stable conformation.  The inclusion of 
polymeric additives can be used to further control the structure, and thus the release 
properties, of the construct.  The included bioactive agent is evenly distributed 
throughout the construct.  Delivery of the drug is then controlled through a diffusion-
mediated release which is dependent on the surface area of the implant exposed to 
aqueous environment (blood and living tissue).    
 
 
Figure 3.1: Theoretical mechanistic diagram of OC system introduction into an 
aqueous environment. Red indicates the hydrophobic domain of the polymer.  Orange 
indicates the hydrophilic domain of the polymer.  Green indicates the hydrophilic 
diluent.  Blue indicates the aqueous environment. Source: “Intravaginal Drug 
Delivery” in Polymers for Vascular and Urogenital Applications (S.W. Shalaby, 
K.J.L. Burg, W.S. Shalaby, eds.) J. M. Olbrich,  W.S. Shalaby,  G.H. Hilas. Taylor & 
Francis Group, LLC (2012) 
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Upon exposure, the hydrophobic portions of the copolymer chain orient themselves to an 
inner core, while the hydrophilic portions form the outer regions of the delivery depot.  
Following this orientation, a multi-layered construct is developed through which release 
of the drug payload, homogenously distributed within, is achieved by diffusive release.  
This diffusion can then be modulated through modifications to either the hydrophobic or 
hydrophilic segments of the chains. 
 
The novelty of this platform technology lies in the ability to modulate nearly any of the 
variables.  Release speed, degradation period, and even gel formation speed can be 
tailored to the exact needs of the individual application through manipulation of the 
described portions of the system.  The major portions of such a system are discussed 
more thoroughly subsequently. 
 
Polymers 
The OCs are novel polymers capable of sustained controlled release of a pharmaceutical 
payload in the presence of an aqueous environment
77,78,79
. These polymers are prepared 
through a bulk, ring-opening, multi-step polymerization of monomers and short chain 
polymers including lactide, glycolide, trimethylene carbonate, diisocyanate and 
polyethylene glycol, depending on the intended application.  An example of the OC 
family is OC9.  The polymer is composed of polyethylene glycol (PEG; Mw=400) and 
DL-lactide/glycolide (80/20) blocks.  The initial step in the polymerization of such an 
agent involves extensive drying of PEG 400, which serves as the initiator, under vacuum 
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in a reaction flask. The metallic based catalyst is then added to the flask.  To construct the 
prepolymer, cyclic monomers (DL-Lactide (DLac) and glycolide (Gly)) are added.  Ring-
opening of the cyclic monomers and chain growth of the polymer occurs.  Block 
structures of PEG and the absorbable monomers, respectively, are prepared.  
Polymerization is allowed to proceed under elevated temperature to completion.  
Completion is monitored through gel permeation chromatography (GPC) analysis of 
molecular weight.  Once the prepolymer has been prepared, the second polymerization is 
initiated.  This step is performed by the addition of diisocyanatohexane (diiso) to the 
reaction flask.  The polymer is then catalyzed with heat to allow the linkage of the diiso 
units to the prepolymer.  Following the completion of polymerization, purification is 
performed on the product to remove impurities and unreacted monomer.  Purification is 
executed through the dissolution of the full contents of the reaction flask in 
tetrahydrofuran (THF).  Once the contents of the flask have been solubilized, a small 
amount of isopropyl alcohol (IPA) is added to ensure that free diiso groups have been 
neutralized.  The solution is then poured into a chilled aqueous non-solvent to precipitate 
the desired polymer.  Polymer is subsequently dried on Teflon® sheets under low heat 







Table 3.1: The OC Polymerization: A General Procedure 
Step Description Chemical Example 
1 
Diol is dried in a flask 
under vacuum.  This 
serves as the initiator. 
 
2 
Heavy metal compound 




Cyclic monomers are 
added for the pre-
polymerization.  A ring-






Chain extending agent is 






Organic solvent is added 






Isopropanol is added to 
neutralize free floating 





The entire solution is 
then poured into ice 
water (H2O).  Resulting 




The result of such work is an absorbable block polyether-ester-urethane (PEEU) or 
polyether-ester-carbonate-urethane (PEECU) copolymer (the latter if trimethylene 
carbonate is used). These polymer structures are amphiphilic in nature, containing both 
hydrophobic and hydrophilic segments joined with flexible urethane linkages 
(contributed by the diisocyanate linkages). Polymeric properties have been manipulated 
by changing the monomeric composition and order/structure. The amphiphilic state of 
such polymers allows the unique formation of a polymeric construct when the polymer is 
exposed to water. The hydrophobic portions, contributed by the lactide and glycolide 
blocks, of the polymer orient to the inner core of the polymer while the hydrophilic 
portions, contributed by the PEG blocks, are presented to the aqueous environment. The 
inclusion of the urethane portions allows the polymer to reach this thermodynamically 
favorable conformation at an unparalleled speed. This rapid (fully complete in less than 3 
minutes) formation allows circumvention of the normal “burst” effect in delivery of a 
pharmaceutical which usually plagues such technologies. This gelation was quantified 
using an Anton-Parr Rheometer (Physica MCR 301). The rheological analysis of one 







Figure 3.2: Complex viscosity over time for gelation of OC polymer and organic 
solvent 
 Due to the rapidity of gelation, little (<5%) drug is lost during evacuation of the diluent 
and bolus formation. Thus, this series of polymers has unique properties not previously 
explored.  These polymers are constructed from generally well characterized and safe 
monomers used in many materials and devices already on the market which should allow 
Food and Drug Administration acceptance and eventual marketing.  Preliminary 
cytotoxicity data has been gathered on a majority of the samples, resulting in scores of ‘0’ 
according to International Organization for Standardization (ISO) 10993-5 testing. This is 
the best score possible on the ISO scale and analogous to a rubber stopper control test.  





Table 3.2: Pertinent Properties of OC9 Lot 1 Purified 
Property OC9 Lot 1 Purified Values 
Composition PEG400 // DL Lactide/Glycolide 
Prepolymer to diiso molar ratio 1 to 0.8 
Number average molar mass (Mn) 10,240 Da 
Weight average molar mass (Mw) 18,566 Da 
Polydispersity index (PDI) 1.81 
Differential scanning calorimetry 
(DSC) 
No thermal events between 25 and 260 °C 
Mass loss at 6 weeks 17.6 % 
Mass loss at 9 weeks 55.4 % 
  
Composition and pre-polymer ratio were calculated using monomer values.  Molecular 
weights and PDI were gathered from GPC analysis on a Waters GPC system using a four 
column set-up consisting of Styragel® 7.8 x 300 mm columns using dichloromethane as 
the mobile phase.  DSC was performed on a Perkin Elmer DSC 6 with a heat scheme of 
20-300°C and a heating rate of 20°C/minute. Mass loss studies were conducted in vitro 
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using laboratory balances, over a period of 4-12 weeks depending on polymer, with 
storage at 37°C in presence of phosphate buffer (physiological pH 7-7.5).  
 
From this data, many important facets of the OC polymer can be seen.  First, the system 
is degradable in vitro, as is evidenced by 55% mass loss after 9 weeks.  However, the 
majority of the construct will still likely be present after 6 weeks, allowing a window of 
controlled delivery.  It is also interesting that the degradation process appears to 
accelerate, which stands to reason as such a process is often self-catalyzing due to 
degradation byproducts and the increasing local acidity of the construct. The PDI 
indicates that a rather wide range of polymer chain lengths are produced, showing the 
polymer does exhibit some heterogeneity. Furthermore, the lack of thermal events 
reported by the DSC indicates that the polymer produced is amorphous.  This likely aids 




The OC gels alone are too viscous for easy application into the body through most 
normal methods.  Accordingly, a method of dilution was developed for these samples that 
allows delivery through a standard Leur-lok® needle and syringe.  This ability entails the 
dissolution of the OC polymer in a water-miscible polymeric diluent such as PEG.  Once 
dissolved, the polymer is injectable.  The water-miscible diluent then evacuates into the 
surrounding environment, precipitating the other solubilized components and allowing 
gelation of the desired depot.  Low molecular weight PEGs such as 200, 400 and 600 Da 
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are used for this solubilizing purpose as the PEG itself must be a non-viscous liquid at 
room temperature.  PEG has been shown to be biocompatible and does not elicit a 
dramatic/malignant immune response upon injection into human tissue. 
 
Experimentation into modification of PEG to aid delivery has also been investigated.  
The purpose of end-group modification is to make slight changes to the polymer-diluent 
interaction.  The two major modification schemes used in this work are acetylation and 
succinylation.  These processes in general involve the introduction of a functional group 
compound, succinic anhydride in the case of succinylation, into an organic solvent at a 
low weight percentage.  The solution is then heated and stirred mechanically to dissolve 
the compound.  Once the compound is dissolved, PEG 400 is added to the flask.  The 
temperature is increased and the reaction stirred for an extended period of time.  After 
cooling to room temperature, the contents are poured into centrifuge tubes and the flask is 
rinsed with organic solvent to collect as much of the polymer as possible.  The product is 
centrifuged and the organic solvent supernatant is decanted.  Acetone is added to the 
tubes and then sonicated to break up the centrifuged pellet.  Finally, the polymer is placed 
under a hood for air drying before being placed in a vacuum oven at room temperature 
overnight.  In the case of PEG, a diol which possesses terminal hydroxyl groups, 
acetylation was employed to create acetylated PEG 400 (denoted as G4A).  This polymer 
was shown through acid number testing to have converted terminal groups to acetyl 
groups, while still maintaining the desirable viscosity of stock PEG.  G4A was used 




Polymeric additives are used to control 
the formation of the construct.  These 
polymers can serve in myriad ways, 
depending on the given needs of a 
certain application.  They can be used 
to increase the overall hydrophilicity of 
a construct and thus slow release.  
Conversely, they can be large 
molecular weight or branched 
structures that allow perfusion of water into the delivery construct, which in turn 
increases the area for diffusion and thus the overall rate of delivery (Figure 3.3).  Beyond 
this simple additive formation manipulation, charged additives can be used to induce 
drug/additive interactions which, in effect, produce hybridized drug/polymer salts. Work 
has gone into determination of additive and polymer pairings which yield desired 
characteristics.  These delivery systems range from 3 day rapid delivery to linear release 
over a period of weeks capabilities, and can be tailored to specific applications in 




Figure 3.3: Theoretical demonstration of 
mechanism of large molecular weight 
additive interaction with depot formation. 
Purple circle indicates additive. 
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Injectability Checks 
The proposed system is intended to be capable of localized injection.  The major 
objective of the diluent portion of the system is to solubilize the OC polymer.  The OC 
polymer itself has been designed to allow superior precipitation mechanics.  Diluent has 
been included in other precipitation systems as mentioned in Chapter 2; however, these 
systems generally require large amounts of diluent for solubilizing the chosen polymer.  
Because of this, as the mainly solvent system precipitates from the polymer, it generally 
carries a large portion of the pharmaceutical payload from the delivery construct.  This is 
a major cause of the well-documented “burst-effect”.  To this end, the OC system should 
be deliverable through an 18 gauge needle with the minimum amount of diluent required 
for room temperature delivery.  This point was tested with a number of OC polymers as 
well as non-OC polymer controls, with G4A diluent at diluent weight percentages of 40, 
33, and 20%.  This testing was conducted with BD Precision Glide Needles (size 
18G1½”) and 1 milliliter BD Leur-Lok
tm
 syringes.  The results of this testing can be seen 
in Table 3.3 with “Passing” being defined as system being capable of moving through the 








Table 3.3: Injectability of Multiple Polymers in Differing Diluent Percentages 










Higher Mw OC using 
a higher Mw PEG 
prepolymer, slightly 
crystalline 
Passes at Room 
Temperature 




Similar to OC16 with 
less PEG content 







Passes at Room 
Temperature 






Similar to OC9, with 
higher PEG content 
to encourage better 
flow 
Passes at Room 
Temperature 




OC4-S Succinylated OC4 
Passes at Room 
Temperature 






From this data, many conclusions can be reached.  First, the inclusion of the urethane 
linkage and PEG segments in the OC polymers does encourage solubility and flow when 
combined with a PEG based diluent.  This can be seen when comparing any of the OC 
polymers to the non-urethane-linked or PEG containing controls.  Secondly, as expected, 
the amorphous nature of the OC polymers is also a positive influence in regard to this 
goal.  The more amorphous OCs passed more easily when compared to the semi-
crystalline OC16 and OC12, which passed more easily in turn than the even more 
crystalline non-OC polymers.  Interestingly, a higher PEG content in the base polymer 
had effect in one instance (OC4 vs. OC9) while not in the more crystalline instance 
(OC16 vs. OC12).  This can possibly be attributed to a limitation of the experimental set-
up as the observations are strictly qualitative and therefore the resolution of differences 
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between materials is limited by human observation.  The final observation of note is the 
fact that succinylation does not make OC4 more difficult to inject, but rather appears to 
increase the injectability of the system.  This can likely be to the inclusion of extra 
oxygen groups on the base polymer, increasing the affinity of the base polymer to the 
heavily oxygenated PEG.  With this information in mind it can be concluded that OC9 in 
a 67/33 weight percent mixture can be injected through an 18 gauge needle in a room 
temperature setting. 
 
Strengths of Such a System 
With injectability determined, the described system can be used for intratumoral 
perfusion of solid tumors, transarterial chemoembolization treatment of eligible cancers, 
and systemic administration of the desired bioactive agent.  The area most likely for use 
of such disruptive technology is localized chemotherapy delivery.  Such a system, 
assuming controlled delivery, has many advantages over other drug delivery mechanisms 
such as microspheres and thermogelling polymers with regard to such therapy.  These 
include but are not limited to: 
 Reduced systemic toxicity due to the local delivery of such a system 
 Higher concentration of the drug at the desired site  
 Efficient use of drug through near complete (e.g. ~100%) delivery from 
constructs and minimal loss in formation  
 Lower daily drug requirements due to increased efficiency  
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 Continuous exposure of drug to target site, reducing the ability of the tumor to 
regrow or develop resistance  
 Perfusion of the tumor and delivery to the entire malignancy  
 Negation of the burst effect to allow targeting of a specific therapeutic window 
 Independence from oscillating physiological conditions such as temperature of 
tumor environment for formation and delivery 
 
With these advantages in mind, drug delivery from this system will be investigated to 
determine the feasibility of using such a system in treatment of solid tumors requiring 
constant exposure of chemotherapy.  The goal of release should be a semi-linear first-
order release of drug to allow constant controlled exposure to the tumor of the 
pharmaceutical payload.  The release of this OC system is explored and discussed in 












DELIVERY OF MODEL HYDROPHILIC DRUG AND EVALUATION OF 
VARIABLES THEREIN 
Introduction 
In continuation of the description and evaluation of the system that began in Chapter 3, 
release was evaluated with respect to multiple variables within the OC delivery system.  
In each of the following studies, doxycycline hyclate (DOX) was used as a model drug.  
DOX is a well characterized and readily available hydrophilic drug used to treat myriad 
conditions in the clinic at a relatively low cost.  Doxycycline’s cost-effective nature 
allows a large screening process to pinpoint potential studies to undertake with the much 
more expensive platinum drug carboplatin (CAR).  CAR and DOX are both similar in 
hydrophilic nature and similar in molecular weight, furthering the argument for use of 
DOX as a model drug.  Finally, DOX release will be useful for potential indications 
where large scale broad spectrum antibiotic use may be of benefit, such as treatment of 
osteomyelitis or bacterial overgrowth in the gut or female reproductive tract. 
 
DOX is also an excellent model drug as it is easy to assay with reverse phase high-
performance liquid chromatography (RP-HPLC).  This positive attribute can be attributed 
to the hydrophilic nature of the drug as well as the presence of the multiple chromophors 
present in the molecule.  The benzene structures impart much of the resonance to allow 
HPLC Ultraviolet detection; therefore, an HPLC method was developed for detection of 
doxycycline in phosphate buffer.  This analysis was conducted using a Waters (Milford, 
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Massachusetts, USA) HPLC system.  This system is composed of a 717+ Autosampler 
connected to a 1525 Binary HPLC pump.  Analysis was performed with the integrated 
2966 photodiode array detector system (see Chapter 5 for more detail on HPLC and the 
HPLC system).  Water’s Empower software and an in-line degasser were used to 
supplement this arrangement. 
 
The mobile phases for such analysis were ultrapure water and acetonitrile (ACN), both 
doped with 0.1% trifluoroacetic acid (TFA).  A Waters® reverse phase C18 column was 
used to separate the drug from the mobile phases.  The optimum method for doxycycline 
detection with the described system incorporated a gradient method, as described in 
Table 4.1.  All samples were examined with at least a 10 minute equilibration step prior 
to analysis to ensure method accuracy.  This analysis yielded a well-defined 
chromatogram, as seen in Figure 4.1. 
 
Table 4.1: Optimized Gradient HPLC Method for Detection of Doxycycline 
Parameter Value 
Initial Mobile Phase Composition 77% Water/23% ACN 
Final Mobile Phase Composition 62% Water/38% ACN 
Run Time 10 minutes 
Flow Rate 1 mL/minute 
Approximate Retention Time 9.3 minutes 





Accurate and repeatable analysis of doxycycline allowed the preparation of multiple 
standard curves.  Standard curves were developed from HPLC analysis of known 
concentrations of doxycycline.  Standard curves were always found to be linear with an 
R
2
 value of greater than 0.995.  The linear coefficients (slopes) of the curves were then 
used to analyze the unknown results from the experimental runs.  An example of a 
standard curve obtained can be seen in Figure 4.2. 
  
 
Figure 4.1: Example chromatogram of doxycycline HPLC run 
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The development of robust standard curves allowed the progression of the project to in 
vitro release studies.  Standard curves were generated monthly to ensure accurate analysis 
of data.  With the drug described and analytical ability ensured, the following general 
method was used to evaluate the difference in drug release. After mixing the components 
for the desired system, the drug-loaded polymer was evenly distributed into three glass 25 
ml vials with approximately 1 gram of delivery system.  Gel was then allowed to flow out 
over several hours, to occupy the bottom surface of the vial to allow a reproducible 
starting surface area for each test. Once the gel evenly coated the bottom of the vial, 10 
milliliters of phosphate buffer (pH 7.2) was added to each vial.  The samples were then 
incubated at 37 °C, with gentle gyration, to simulate physiological conditions.  At each 
time period, the buffer was removed from each sample, filtered through an Acrodisc® 
Figure 4.2:  Example of doxycycline standard curves utilized throughout study 
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0.45 µm filter to remove any insolubles, such as polymer degradation products, and 
analyzed by HPLC. The results of this analysis were compared with those of the standard 
curve to allow quantification of drug release from the samples.  Using DOX as a model 
drug, multiple delivery systems were screened for effect on drug release.  
 
Liquid OC Comparison 
The OC polymers can be divided into two different groups, the liquid and the solid OCs.  
The distinguishing feature between the two types is the presence or absence of crystalline 
regions within the polymer orientation.  The liquid OCs (OC2 through OC10) are the 
more amorphous of the two groups, and tend to be more easily injected than the 
crystalline OC11-OC16.  In order to examine the effect on drug delivery from the liquid 
OCs, drug release from OC2 through OC10 was tested.  The results of this testing is 
presented in Figure 4.3 on the next page. 
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From this information it can be seen that OC9 and, to a lesser extent, OC2 appear to be 
superior in regard to sustained release of the model drug doxycycline.  Many conclusions 
can be drawn from these results.  These polymers all have similar hydrophilic PEG 
regions and the associated polyurethane regions.  The difference between these polymers 
lies within the composition of the hydrophobic (e.g. non-PEG) block.  First, OC5, 6, 7, 
and 8 all incorporate the monomer trimethylene carbonate (TMC) in the hydrophobic 
region.  Despite changing percentages and combinations with lactide and glycolide, 
similar result profiles are seen.  From this information, TMC-containing OC polymers do 
not readily appear promising for the desired release profile. 
 
OC4 and OC3 are similar in chemical structure to OC2, but possess a weight average 
molecular weight half that of OC2.  These polymers consist of a lactide/glycolide 
Figure 4.3: Doxycycline release from the liquid OC polymers (n=3)  
Note: Error bars omitted for clarity. 
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hydrophobic block which exhibits promise in controlled release.  As is often 
hypothesized in the area of controlled release, a higher weight average molar mass (Mw) 
polymer allows increased retention of the pharmaceutical payload.  The increased Mw 
OC2 exhibits a reduced burst effect as well as closer to zero order release of the 
subsequent drug.  OC10 is also similar in composition to OC3 and OC4, but uses L-
lactide rather than DL-lactide.  This change in lactide monomer conformation does not 
have a large effect on drug release from these polymers.  
 
OC9 has the most markedly different release profile within this experimental group.  OC9 
differs from the other liquid OCs in the base polymer composition percentage of PEG.  
OC9 has a smaller hydrophilic portion than the other OC polymers.  This reduction of 
hydrophilicity, while allowing the hypothesized phase separation gelation, appears to 
help controlled delivery.  This can be attributed to the concept that DOX, a hydrophilic 
drug, will preferentially diffuse through the hydrophilic domains of the release construct.  
By limiting these domains, and thus the surface area of the hydrophilic areas, drug release 
will be inhibited.  The behavior of OC9 lends credence to this idea, i.e. the greatly 
reduced initial release and greater control as compared to the other OC release profiles. 
 
No polymer system tested exhibited greater drug release than 60% of payload initially, 
and each had quantifiable release for subsequent days.  This result suggests that the 
system is effectively encapsulating drug in all instances and releasing at least a portion of 
the administered drug in a controlled manner.  Also, it is evident that at day 13, the date 
 71 
of termination for these studies, there is not 100% release of the hypothesized payload.  
This payload is calculated based on the drug percentage of the original polymer 
preparation and the amount of gel administered in each test sample.  In order to more 
fully understand the system, a better accounting of drug would be helpful.  To this end, 
an extraction method was designed. 
 
The extraction method entails the application of 5 milliliters of acetonitrile (ACN) 
following the completion of the release testing, which in this case is following day 13.   
The ACN dissolved the polymer matrix and thus releases the remaining captured drug 
into solution.  The polymer/ACN mixture is allowed to shake at room temperature until 
the polymer solid is no longer apparent in the release vial.  This mixture is then combined 
with 5 milliliters of HPLC grade water to create a bi-phasic mixture.  At this point the 
mixture becomes a cloudy liquid, as the polymer behaves as would be expected and 
preferentially separates from the aqueous portion of the mixture, theoretically leaving the 
majority of the hydrophilic drug in the aqueous portion.  To further this separation, the 
mixture is centrifuged at 13000 RPM for 10 minutes.  The resultant supernatant is then 
removed from the centrifuge vials and is thus finally devoid of the higher molecular 
weight polymer precipitate remaining in the centrifuge vial.  This supernatant, clear and 
theoretically aqueous with solubilized drug, is then filtered and analyzed through HPLC.  
This method was tested with a known drug value and was evaluated to have a 90% 
extraction efficiency which was deemed adequate by team decision for evaluation of 
 72 
these OC systems.  Each of the liquid OC release systems was tested using this extraction 
technique, and the results of this analysis can be seen in Table 4.2. 




% Drug Released at Day 13 





2 82.5 5.5 12 
3 84.5 0 16.5 
4 85 0 15 
5 73 1 26 
6 76 2 22 
7 81 1 17 
8 78 2 20 
9 58 35 7 
10 80 2 18 
 
As can be seen from this table, OC9 is the only polymer with a large amount of drug 
remaining within the delivery construct following Day 13.  In the cases of the other 
release profiles, the extraction results allow a reasonable degree of certainty that release 
has reached a completion.  Also, the extractions allow a mass balance showing that, in 
most cases, approximately 80% of the theoretically included drug is accounted for.  
While not optimal, it is important to note that the extraction methodology is not 100% 
efficient and that there are many opportunities for drug to be lost throughout the release 
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study process.  Thus, the results of these studies suggest that the OC9 system is the most 
promising of the liquid OCs in terms of attaining a semi-linear release profile. 
 
Solid OC Release Profiles 
Following testing of the liquid OCs, polymers from the solid OCs were tested.  These 
polymers have larger hydrophobic block components, have higher molecular weight PEG 
components in the hydrophilic domains, and have higher Mw values than the liquid OCs.  
These polymers tend to gel into harder constructs but are difficult to administer through 
the desired injection system, as described in Chapter 3.  These polymers were tested in 
the described release format and the results of this testing can be seen in Figure 4.4. 
 
Figure 4.4: Release profiles of the solid OC polymers (n=3)  
Error bars omitted for clarity 
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From this data it is evident that the solid OC polymers do not have the same aptitude for 
controlled release that the liquid OC polymers have.  The large hydrophobic component 
of these polymers, combined with the crystalline behavior inherent to such design, likely 
inhibits the encapsulation/depot formation seen in the liquid OCs.  Also, the higher Mw 
PEG components of the hydrophilic domains also provide less “flexibility” than the lower 
Mw sub blocks used in the liquid OCs.  From this less favorable data, the decision was 
made to move forward with the liquid OCs for future testing. 
 
Additive Use – A6 
Throughout the development of controlled release technology, much effort has been put 
toward the use of additives to further control the release from a construct.  In this regard, 
four different additive groups were explored in relation to DOX release from the OC 
system.  The first additive investigated was A6.  This polymer is low molecular weight 
acid terminated polyglycolide. This polymer was included in polymer delivery systems at 
5 and 10 weight percent loadings.  The effect on release of DOX was quantified using 
OC2, OC4, OC6 and OC9.  The results of this testing are shown in Figures 4.5, 4.6, 4.7, 

















Figure 4.5: Effect of doxycycline release from OC2 system and the effect of A6 












Figure 4.6: Effect of doxycycline release from OC4 system and the effect of A6 













Figure 4.7: Effect of doxycycline release from OC6 system and the effect of A6 












Figure 4.8: Effect of doxycycline release from OC9 system and the effect of A6 
inclusion (n=3, error bars indicate 1 standard deviation) 
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The results from this testing support the idea that polyglycolide (PG) microparticles can 
impact release.  In each instance, better defined in the OC6 and OC9 test batteries, A6 
allows slow release from the constructs and encourages a more linear release profile.  
OC9 shows that A6 is predictably capable of influencing release as the amount of the 
additive in the composition increases.  Greater than 10 weight percent A6 compositions 
were not tested as these compositions proved difficult to inject and therefore would not 
be viable clinically. 
 
While these results do show that A6 can be used to control drug release, the mechanism 
through which this is affected is not perfectly clear.  There are two potential theories for 
the way that A6 causes these changes.  The first involves the effect that A6 has on the 
depot formation.  A6 is a large element in comparison to the flexible OC polymers.  The 
presence of these microparticles could cause disruptions in the formation of the typical 
polymer depot structure, again affecting the hydrophilic delivery domains.  Also it stands 
to reason A6’s surface will protonate in the presence of an aqueous environment, 
allowing stronger binding to both the positively charged doxycycline and the OC matrix.  
This is supported by the fact that, as A6 quantities are increased, release is further 
decreased, indicating that the A6 is potentially limiting this delivery/diffusive surface 
area further. 
 
A second theory involves a potential drug interaction between A6 and doxycycline 
hyclate.  Doxycycline hyclate is a salt, like most common antibiotics, composed of the 
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doxycycline freebase drug and the hyclate combination of hydrochloric acid, water, and 
short chain alcohols.  This drug complex has the potential to either interchange some 
portions of the hyclate with the similar PG/PEG composition of A6 or simply form a 
larger complex with a drug/polymer conjugate.  This conjugate would then, in theory, be 
slower to diffuse out of the complex.  This theory is reinforced by the slowing of the 
release rate when A6 is used in the delivery systems. 
 
While the exact mechanism of A6 is not fully understood, it is clear that additives can 
have a great effect on drug release from the OC system.  With this knowledge, other 
additives, and their effect on the system, will be explored. 
 
SW Polymer Additives 
After the success of A6, the SW family of polymers was developed and synthesized.  
These polymers are low molecular weight poly-ether-co-glycolide copolymers. These 
polymers were tested for release, the results of which can be seen in Figure 4.9 on the 
next page. These additives show even greater promise than the A6 polymers in achieving 
linear release.  The major difference between the A6 and SW polymers is the inclusion of 
ether segments in the SW polymer.  These segments are added through the incorporation 
of PEG in the copolymer.  A comparison of A6 and SW results can be seen in Figure 4.10 
on page 77.  The decreased hydrophobicity of the construct likely helps maintain the 
hydrophilic drug. Perhaps most important in terms of SW effect on release, the entire 












Figure 4.9: The effect of the SW family of additives on release from the OC9 











Figure 4.10: Comparison of A6 and SW2: effect on DOX release from OC9 (n=3, 
error bars indicate 1 standard deviation) 
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Figure 4.11: Release of DOX from OC9/SW2 system over 42 days with line of 
best fit (n=3, error bars indicate 1 standard deviation)  
 
From this graph it is apparent that SW additives can have a great effect on the release of 
DOX from the OC system.  A relatively linear release is achieved.  As can be seen from 
the best fit line in Figure 18, a linear fit garners a R
2
 value of 0.9861.  This type of release 
would be highly advantageous for systems requiring strict quantity control due to a 
limited range of acceptable concentrations between the lowest efficacious dose and the 






The BTO3 additive is a tri-axial ε-caprolactone-based polymer.  This polymer was 
studied to examine the effect of additive structure on release. As a tri-axial polymer, 
BTO3 often behaves differently than the linear copolymers described so far.  
Succinylation with BTO3 magnifies the effect of a potentially charged end-group on 
release; the resulting polymer is denoted BTO3S.  DOX release results from BTO3 and 
BTO3S are compared to A6 in Figure 4.12. 
Figure 4.12: Effect of doxycycline release from OC4 system and release differences 
between BTO3 and BTO3S (n=3, error bars indicate 1 standard deviation) 
Both BTO3 polymers appear to be superior in relation to A6 (OC4A), demonstrating 
reduced release, even in the fast releasing OC4 system.  This reduction is likely due to the 
triaxial nature of BTO3 and the hydrophobic nature of the BTO3.  However, BTO3 was 
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not suitable for large scale use in the system, as the caprolactone nature of the polymer 
caused injection difficulties, imparted a waxy, brittle quality to the final construct, and 
the mass loss for BTO3 is a wide window.  Also, it is interesting that the succinylation 
(OC4BS) of the BTO3 creates a wide variation in release.  This could be attributed to 
either (1) the lack of efficiency of the succinylation process, or (2) disturbances in the 
polymer matrix from the increased charge presence.  If the succinylation process is not 
efficient at affecting the BTO3 polymer homogenously, the charges/end group 
modification will vary from sample to sample, effecting variability as seen in this sample. 
 
Diluent Effect on Release 
As the OC polymers require a diluent for administration, the effect of this diluent should 
be examined to completely understand the system.  Polyethylene glycol with Mw of 400 
(PEG 400) was chosen as the initial diluent for many reasons.  PEG 400 is a liquid 
polymer with a relatively low viscosity, is already used in many medical applications, 
and is effectively miscible with the OC polymers with the application of heat.  The 
experimental diluent G4A (acetylated PEG 400) was compared to PEG in many instances 
to determine the effect of end-group chemistry on depot formation and subsequent 
release.  Figure 4.13 illustrates the difference of release on the OC9 system when 
comparing G4A and PEG 400 as the diluent portion. 
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Figure 4.13: Comparison of DOX release from OC9 system between PEG and G4A 
diluents (n=3, error bars indicate 1 standard deviation) 
 
The difference in release between the two profiles, while not profound, is apparent in the 
initial two week period of release.  While potentially helping the system in terms of 
injectability and shelf-life prior to injection, G4A appears to disrupt the initial release 
kinetics of the system.  This finding was further clarified by studies, see Figure 4.14, 
conducted in OC4 systems, which are already plagued by quick release as seen earlier, 
but exacerbated by the use of G4A.  Also in this graph can be seen the effect of G4S.  
G4S is succinylated PEG 400, which was prepared to visualize the effect on release of a 
different end-group modification. 
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Figure 4.14: Effect of doxycycline release from OC4 systems with varied diluents (n=1) 
 
As can be seen, neither G4S or G4A appears to be a promising replacement for PEG 400 
when striving to attain linear release from the OC delivery systems.  These end group 
modification techniques appear to cause the diluent to carry more drug as they evacuate 
the depot formation.  This is seen through the almost tenfold increase in burst between 
the PEG and modified diluents.  From this data it stands that PEG-based diluents are 
capable of use with the system, but unmodified PEG should be used to best achieve linear 
release.  Next, it is logical to explore the effect of varying diluent component percentage 
of the OC system.  The effect of a 50/50 polymer/diluent system versus a 67/33 system is 
seen in Figure 4.15. 
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Figure 4.15: Comparison of DOX release from OC9 system between a 67/33 and 50/50 
system of G4A (n=3, error bars indicate 1 standard deviation) 
 
Interestingly, these samples show that, while there is little initial burst difference between 
more or less diluent, there is a significant effect on release in the early days of the system.  
This leads one to believe that the larger diluent percentage may not be able to fully 
evacuate the depot initially, but rather, when it is able to escape, carries a large amount of 
drug with it.  The 50/50 composition, while injectable, does not control release as well as 
the polymer dominant system. Also, due to the reduced polymer presence, the 50/50 
mixture does not form as repeatable or as strong depot following injection as the higher 




Blending of OCs and Effect on Release  
The OC polymers were also designed to be amenable to blending processes.  Polymer 
blends are often employed to derive properties from multiple polymers into a single 
polymer.  Blends differ from copolymers as the polymeric chains and units are not 
themselves covalently joined, but rather remain separate while acting as a single unit.  In 
essence the OC delivery system as a whole is a blend of OC polymer, diluent polymer, 
and polymeric additive.  The next logical step of this progression is to examine the effect 
of blending multiple OC polymers together to examine the effect on release.  The 
blending is simple and achieved through physical mixing of the OC polymers, both 
together in the same step of the system preparation as the diluent.  To first examine the 














Figure 4.16: Comparison of DOX release from blended OC systems (n=3 for OC9 and 
OC4 release, error bars indicate 1 standard deviation) 
 
From this data it can be seen that blending is indeed possible as all three of the release 
curves for the blends fall approximately between the release curves for OC4 and OC9.   
Blending has many benefits to systems such as the OC system.  Primarily it allows the 
development of a more modular platform without the use of complex polymerizations.  
Also, secondary properties including injectability and depot formation can be tuned to a 
specific application.  The successful blending of the OC polymers opens interesting doors 
to tailorable delivery systems for individual applications.  The ability to use multiple 
drugs for myriad indications provides an opportunity for personalized medicine.  This 
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idea is discussed in more detail in Chapter 5.  Following this success, blending was 
examined more thoroughly through a series of tests. 
 
Figure 4.17: Comparison of DOX Release from OC Blends (n=3, error bars indicate 1 
standard deviation) 
 
Figure 4.17 reveals that 1:1 blending of OC4 and OC9 with OC2 produces release curves 
which contain characteristics of both of the single polymer systems.  The OC9 blend still 
releases at a lower rate than the OC4 blend, but both blends show release similar to that 
of OC2.  Also, both releases still show acceptable repeatability and therefore blending 
can be expected to combine characteristics of the composite polymers. 
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Figure 4.18: Comparison of DOX release from OC blends of differing diluent 
composition (n=3, error bars indicate 1 standard deviation) 
 
Figure 4.18 shows the effect of diluent change in a blended system is similar to that of the 
unblended or single system, specifically, the larger the diluent component, the higher the 
initial release. From the gathered blending data it is reasonable to postulate that blending 
OC polymers into a single system will result in hybridization of release profiles.   These 
blended results, following initial observation, appear to follow the results one would have 




Many methods to control a water soluble drug are presented in the context of the OC 
system.  These methods involve the manipulation of assorted variables within the system. 
Release from the OC system has been shown from a quick 3-day release to an almost 
linear release over 42 days.  Such modularity with the OC system speaks to its potential 
use as a platform technology.  If the OC system can be shown to be useful and 
controllable with a variety of drugs, such a system could have many uses in a wide range 

















RELEASE OF OTHER DRUGS FROM THE OC SYSTEM; USE OF REVERSE 
PHASE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY  
 
Following the examination of doxycycline as a model drug, other drugs were considered 
for release quantification, in conjunction with the OC system.  Various bioactive agents 
were investigated to show the system’s modularity and potential as a platform 
technology. In these instances the ability to quantify drug release was vital.  Accurate, 
rapid and repeatable detection of pharmaceutical agents allows comparisons between 
drug delivery constructs prior to in vivo studies as well as identification of therapeutic 
levels in samples both in vitro and in vivo.  Perhaps the foremost scientific method for 
monitoring therapeutics is high performance liquid chromatography (HPLC).   
 
HPLC allows clear and simple quantification of therapeutic presence in a sample, with an 
inherent or induced chromophore, through the detection of bound specimen to the HPLC 
column.  Multiple drugs can be analyzed through this process; methods were developed 
in this research for the pharmaceutics carboplatin, cefuroxime, clindamycin, dicloxacillin, 
doxycycline, metronidazole, paclitaxel, and tobramycin. For each drug: (1) a brief 
background is supplied,  (2) a reverse phase HPLC method is described, (3) a standard 
curve is presented to show the linearity of response for the proposed method within a 
range of absorbances, and (4) release is examined from the OC4 system.  This quick 
releasing system was chosen both to illustrate the cross-utility of the OC polymers within 
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the proposed system as well as to illustrate that most antibiotic regimens tend to be 
shorter in duration than typical chemotherapeutic courses.  Analysis of all drugs was 
performed on a single HPLC apparatus, showing the flexibility of the technology as well 
as the ability to analyze multiple compounds from one machine, allowing laboratories to 
save costs on multiple machines and columns.   
 
HPLC 
HPLC is a widely used method to quantify the presence of a pharmaceutical solute in 
samples.  This analytical method involves the injection of a sample into the 
chromatographic column, which then retains the desired sample from the mobile phase.  
The extracted and bound sample can then be analyzed through a variety of methods, 
which involve the detection of a chromophore of the bound agent.  HPLC analysis is 
superior to other forms of ultraviolet-visible (UV-Vis) quantification due to its ability to 
clearly quantitate material as well as remove material interaction issues inherent in other 
processes
281
.  Despite this distinct advantage, HPLC is a very difficult process, with 
variables such as temperature, column choice, mobile phase composition and mobile 




Column choice is a crucial variable, influencing the efficacy of an HPLC method.  
Columns are offered in a wide variety of types and sizes, but can generally be divided 
into normal phase and reverse phase columns.  These column names relate to the manner 




.  Reverse phase is by far the more prevalent technology at present and involves 
hydrophobic columns and aqueous-based mobile phases.  Commonly used columns in 
reverse-phase HPLC (RP-HPLC) include C8 and C18 columns.  Column choice 
parameters have been covered in the literature
282,283
 and, as RP-HPLC is by far the more 
prevalent, the terms RP-HPLC and HPLC will be used interchangeably in this text as 
they are in literature. 
 
Following the choice of column type, HPLC methods fall into two groups based on 
analytical scheme.  These two schemes are referred to as isocratic and gradient methods.  
Isocratic methods refer to the use of a single mobile phase composition for the entire 
analysis, whereas gradient methods refer to methods which use a changing composition 
through the process.  Isocratic analysis has been considered faster, however gradient 




, and separation of multiple 
compounds in a single sample
285
.  For these reasons gradient analysis is often employed 
in analytical settings where applicable.  When choosing a gradient method, the mobile 
phase is of great concern.  Mobile phases in RP-HPLC usually involve water, acetonitrile, 
and/or methanol and sometimes a dopant agent such as triethanolamine or triflouroacetic 
acid (TFA)
282
.  Because of the large amounts of variables present in such systems, 
method development is quite difficult and results in many methods for analyzing the 
same drug
286
.  For this reason, it is important to select and/or develop the best method for 
a given application’s indication. 
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HPLC System and Parameters 
A single HPLC apparatus was used for the detection of all drugs, allowing limited 
maintenance and ease of work flow interruption between projects.  The column used was 
a Waters Symmetry® C18 5 µm 4.6 x 150 mm column, and the pump was a Waters 1525 
binary HPLC pump.  The pump and column were coupled with a Waters 2996 
Photodiode Array Detector (PDA) for analysis.  All mobile phases were first filtered 
through a Waters four channel in-line degasser prior to injection into the pump housing.  
Mobile phases used were HPLC grade water with 0.1 % TFA and acetonitrile (ACN) 
with 0.1% TFA. A Waters 717plus autosampler was employed to allow multiple sample 
injection. Software for analysis was Waters Empowerer Pro. The flow rate was set at 1 
ml/min.  Note that the methods are described by percentage of ACN mobile phase, 
omitting the complimentary percentage of HPLC composition in the mobile phase. 
 
Method Development: A General Outline 
Methods for each drug were generated specifically for the provided HPLC apparatus.  A 
drug solution of greater than 0.1 mg/ml was prepared in mobile phase solution. If a given 
drug was not soluble at 0.1 mg/ml, the highest concentration found in lab was used.  
Sample was then analyzed on the described HPLC apparatus through a gradient method 
of 5% ACN to 95% ACN over a period of 20 minutes (Figure 5.1).   
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Figure 5.1: A 5-95% run of cefuroxime on HPLC 
The 5% to 95% range was chosen to limit usage of the end ranges of column absorbance 
and therefore enhance the lifetime of the column.  This HPLC trace provides a general 
range for the determination of the second method attempt.  The location of the peak in the 
original run determines the second run, which is prepared with a range of 15% change in 













The mobile phase composition was adjusted until the major eluent peak appeared more 
than 5 minutes after the solvent injection peak, to be assured of peak resolution from the 
solvent front (Figure 5.3).  
 
Figure 5.3: Acceptable method for cefuroxime analysis on HPLC 
Once this resolution was achieved, the method was determined to be acceptable.  
Analytical wavelength for each drug was determined as the wavelength which 
corresponded with the maximum absorbance response compared to the baseline noise for 
the sample peak, as provided by the attached photodiode array detector.  Following 
development of the method, the process was analyzed for reproducibility through 




 value of greater than 0.99 was achieved when correlating micrograms injected and 
absorbance reported. 
 
Antibiotics, the OC System, and Clinical Need 
The following sections each discuss a different bioactive agent. Each of the drugs 
discussed was chosen for method development based on clinical need.  The myriad drugs 
tested show the modularity of the system, and therefore the platform nature of the OC 
technology.  A brief outline is given of the clinical use of the drugs as well as an 
overview of HPLC methodology for each.  The results of method development and 
release testing from the OC system are presented subsequently.  Finally, release eluents 
of applicable drugs were efficacy tested with a model cell line to illustrate release and 
maintenance of drug activity. 
 
Cefuroxime 
Cefuroxime is a member of the cephalosporin family, which displays activity against 
both gram-positive and gram-negative bacteria
287
.  The drug is usually well tolerated by 
patients and is used to treat a wide range of diseases, especially those where 
penicillinases are not advised for use or the patient exhibits allergic symptoms. 
Cefuroxime is a well-characterized drug with many methods for quantification and has a 
prominent chromophore with peak UV absorbance in the 270-280 nm range, making it 
acceptable for HPLC analysis
288
.  The drug is usually used in salt form, with cefuroxime 
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sodium being prevalent.  This form is very hydrophilic and, for this reason, RP-HPLC 
can be used to quantitate drug presence in solution samples. 
 
Cefuroxime sodium salt was determined to be best analyzed through the gradient method 
of 20 to 35% ACN over a time of 10 minutes.  With this method, a peak was found at 
approximately 7.25 minutes.  The best absorbance for analysis for this peak was 
determined to be 275 nm.  A standard curve was prepared of a sample solution injected at 
different injection volumes, resulting in an R
2
 value of 0.9999.  A standard curve is 
shown in Figure 5.4. 
 
Figure 5.4: Cefuroxime standard curve at 275 nm 
From this standard curve, cefuroxime was determined to be analyzable using HPLC, 
allowing quantification of release from the OC4 system.  Batch release studies were 
prepared in a method similar to previously described for doxycycline testing.  Gels were 
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prepared used G4A as a diluent.  A 2%, 5% and 10% loaded cefuroxime gel was 
prepared, to allow comparison of drug content effect on release.  The results of the batch 
release studies can be seen in Figure 5.5. 
 
Figure 5.5: Release of cefuroxime from OC4 gel systems (n=3, error bars indicate 1 
standard deviation) 
Interestingly, cefuroxime was initially quickly released from the OC4 depot.  This is not 
surprising, given it is a highly water-soluble drug and the OC4 system is quick releasing.  
Also, no additives were used to control this burst.  Even with this quick drug release, a 
portion of the loaded drug was released over a period of days following the initial burst in 
each of the three cases.  Drug release was also relatively similar across specimens of each 
of the experimental groups.  More drug was found in cumulative release measurements 
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than was expected in the theoretical mass calculations of the system, which points to a 
need to better control the mixing process of the gel preparation.  Perhaps most interesting 
is that as the weight percentage of drug in the gel was increased, the rapidity of drug 
release was also increased.  This phenomenon was seen in other experimental groups, as 
well as in doxycycline, and points to the fact that drug concentrations must be tightly 
controlled in depot formulations. 
 
To further illustrate the ability of this system to combat infection, eluents were sampled 
and used to treat populations of microbiological growths.  Staphylococcus aureus (S. 
aureus, Moltox) was used as a model organism.  S. aureus was thawed in tryptic soy 
broth and cultured at 30 ºC according to manufacturer instructions.  All eluent samples 
were removed from storage (2 – 8 ºC). At that time, 15 µL of each sample was added to 5 
milliliters of broth inoculated with S. aureus according to 0.5 McFarland Standard (0.05 
absorbance reading). Controls consisted of 5 milliliters inoculated broth. Samples were 
vortexed gently and placed into a 30 ºC incubator overnight. After approximately 24 
hours, relative absorbance was recorded for each sample using a spectrophotometer (600 
nm wavelength).  Relative absorbance was related to percent inhibition through use of 






Table 5.1: Percent Inhibition of S. Aureus by Cefuroxime Eluents 
Eluent ID Drug 
Measured Concentration 





Control A - 
 
0.982 0.00% 
Control B - ug/mL 1.013 0.00% 
Day 1 Cefuroxime 4.15 0.052 94.79% 
Day 2 Cefuroxime 0.84 0.323 67.62% 
Day 3 Cefuroxime 0.33 0.662 33.63% 
Day 4 Cefuroxime 0.12 0.795 20.30% 
Day 5.5 Cefuroxime 0.08 0.88 11.78% 
Day 7 Cefuroxime 0.02 0.991 0.65% 
 
As can be seen from Table VI, clinically relevant cefuroxime dosing is delivered over 
multiple days, with the best effect coming on days 1 and 2.  Inhibitory effects are seen 
until approximately day 7. 
Clindamycin 
Clindamycin is a lincosamide that is finding a wider use in today’s clinic due to the wide 
range of efficacy for the drug
289
.  It can be used to treat infections from staphylococcal to 
anaerobic to even some protozoal infections
290
.  Clindamycin is supplied as a hydrophilic 
salt, traditionally as a hydrochloride.  With this enhanced solubility, RP-HPLC is often 
employed with detection around 200 nm
289, 290
.  Clindamycin HPLC methods are usually 
isocratical
289, 290
 while gradient methods are useful especially as clindamycin is often 
used in combination treatments
285
.   
 
The clindamycin hydrochloride analysis method was determined to be 20% to 35% ACN 
over a period of 10 minutes.  With this method, a peak was found at approximately 8.15 
minutes.  This peak was also determined to have a best absorbance for analysis at 210 
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nm.  A standard curve was then prepared of a sample solution injected at different 
injection volumes, resulting in an R
2 
value of 0.99999.  A standard curve is shown in 
Figure 5.6.  
Figure 5.6: Clindamycin standard curve at 210 nm 
 
From this work, clindamycin was chosen for release analysis using OC4.   Clindamycin 




Figure 5.7: Release of clindamycin from OC4 gel systems (n=3, error bars indicate 1 
standard deviation) 
Clindamycin shows a well-controlled release from the OC4 system following the inherent 
first day release of the system.  Again, a higher release of drug occurred than was 
expected through theoretical measurements, pointing to a need to better control and 
monitor mixing conditions.  These promising results were further confirmed through 
microbiological testing in a manner consistent with that outlined previously.  The results 






Table 5.2: Percent Inhibition of S. Aureus by Clindamycin Eluents 
Eluent ID Drug Concentration Raw OD % Inhibition 
Control A -   0.876 0.00% 
Control B  -  ug/mL 0.944 0.00% 
Day 1 Clindamycin 21.9 0.124 86.37% 
Day 2 Clindamycin 3.5 0.582 36.04% 
Day 3 Clindamycin 2.2 0.124 86.37% 
Day 4 Clindamycin 2.2 0.154 83.08% 
Day 8 Clindamycin 4.0 0.123 86.48% 
 
From this data it can be assumed that a clinically relevant amount of efficacious 
clindamycin is delivered over a period of 7 days when the 10% loaded clindamycin gel is 
observed in vitro. 
 
Dicloxacillin 
Dicloxacillin is a modern member of the penicillin family.  It is penicillinase-resistant, 
allowing use in indications where other members of the group are not effective
291
.  It is a 
highly polar compound which causes difficulty with extraction in many processes
292
.  
Previous work with this drug has involved reverse phase columns and has used detection 




Dicloxacillin salt monohydrate was determined to be best analyzed through the gradient 
method of 45 to 60% ACN over a time of 10 minutes.  With this method, a peak was 
found at approximately 7.33 minutes.  This peak was also determined to have a best 
absorbance for analysis at 225 nm.  A standard curve was then prepared of a sample 
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solution injected at different injection volumes, resulting in an R
2
 value of 0.999.  The 
standard curve is shown in Figure 5.8. 
 
Figure 5.8: Dicloxacillin standard curve at 225 nm 
Following the development of this standard curve, dicloxacillin was examined for release 
from the OC4 system.  Dicloxacillin was tested at 2, 5 and 10 weight percent loadings.  
This data is displayed in Figure 5.9. 
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Figure 5.9: Release of dicloxacillin from OC4 gel systems (n=3, error bars indicate 1 
standard deviation) 
The data, shows that dicloxacillin was released from the OC system.  Also, dicloxacillin 
was analyzed via microbiological assay.  The concentrations measured from the 5% 
weight loaded eluents are listed in Table 5.3. 
Table 5.3: Percent Inhibition of S. Aureus by Dicloxacillin Eluents 
Eluent ID Drug 
Measured Concentration 





Control A  - 
 
0.954 0.00% 
Control B  - ug/mL 0.967 0.00% 
Day 1 Dicloxacillin 12.98 0.07 92.71% 
Day 2 Dicloxacillin 3.22 0.204 78.76% 
Day 3 Dicloxacillin 1.23 0.021 97.81% 
Day 4 Dicloxacillin 0.56 0.075 92.19% 
Day 5.5 Dicloxacillin 0.26 0.314 67.31% 
Day 7 Dicloxacillin 0.08 0.639 33.47% 
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This data suggests that a clinically relevant amount of efficacious dicloxacillin is 




This cytostatic drug has a wide range of uses within the clinic.  Metronidazole is 
prescribed for conditions ranging from rosacea to bacterial vaginosis
295
.  The drug has 
also been shown to sensitize tumors to radiotherapy, beginning its use in oncology
296
.  
For these conditions, the drug is often carried within a gel
297
, with release from the gel 
being an important experimental variable.  For this reason, HPLC is often employed as 
the drug is water soluble, has a strong chromophore, and is used in the described wide 





Metronidazole-free base was determined to be best analyzed through an isocratic method 
of 3% ACN over a time of 10 minutes.  Gradient methods proved difficult due to the high 
water solubility of the drug, and a percentage outside the 5 to 95 % preferred range was 
required.  This method exhibits the effectiveness of isocratic methods with the described 
HPLC apparatus.  With this method, a peak was found at approximately 7.30 minutes.  
This peak was also determined to have a best absorbance for analysis at 275 nm.  A 
standard curve was then prepared of a sample solution injected at different injection 
volumes, resulting in an R
2
 value of 0.999.  The standard curve is shown in Figure 5.10. 
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Figure 5.10: Metronidazole standard curve at 275 nm 
Following the successful standard curve development, release was quantified from a 5 




Figure 5.11: Release of metronidazole from OC4 gel systems (n=3, error bars indicate 1 
standard deviation) 
Metronidazole demonstrated one of the better controlled releases from OC4 amongst the 
drugs observed; it was released in a controlled manner for longer than 1 week.  Also, the 
opposite effect of drug loading was seen with metronidazole, where the higher loaded 
drug amount had a slower release profile than the lower, 5%, loaded construct.  These 
differences are interesting to note as this drug was analyzed as a free base rather than a 
salt.  Also, the drug involved has an inherent charge.  Both of these facts can affect drug 




After these release profiles were prepared, metronidazole was examined by 
microbiological assay as well.  Metronidazole is not effective at inhibition of S. Aureus so 
a different model organism was employed.  Veillonella parvula was employed, as 
metronidazole is known to be effective against this bacterium, which is present in many 
systemic infections. Veillonella parvula was thawed in reinforced clostridial broth and 
cultured at 37 ºC with 5.0% CO
2
 present, according to manufacturer instruction. Broth 
was inoculated with V. parvula according to 0.5 McFarland standard (0.05 absorbance 
reading).  Inoculated broth (5.0 milliliters) was placed in a culture tube for each sample 
tested.  Each eluent was stored at 2 - 8ºC prior to experimentation.  All samples were 
removed from storage; 100µL of each sample was placed into a separate culture tube 
containing V. parvula (prepared as described earlier).  Samples were vortexed gently and 
placed into a 37 ºC incubator with the presence of 5.0% CO2 overnight.  After 
approximately 24 hours, relative absorbance was recorded for each sample using a 
spectrophotometer (600 nm wavelength).  Relative absorbance was related to percent 
inhibition through use of controls.  The results from both 5 and 10 weight percent 








Table 5.4: Percent Inhibition of V. parvula by Metronidazole Eluents 
5% Samples 
Eluent ID Drug Concentration Raw OD % Inhibition 
Control A -    1 0.00% 
Control B  - ug/mL 1.016 0.00% 
Day 1 Metronidazole  68.8 0.04 96.03% 
Day 2 Metronidazole  18.3 0.062 93.85% 
Day 3 Metronidazole  8.7 0.036 96.43% 
Day 6 Metronidazole  5.2 0.05 95.04% 
Day 7 Metronidazole  1.0 0.487 51.69% 
Day 8 Metronidazole  0.5 0.973 3.47% 
Day 9 Metronidazole  0.2 1.072 -6.35% 
10% Samples 
Eluent ID Drug Concentration Raw OD % Inhibition 
Control A -    0.452 0.00% 
Control B  - ug/mL 0.49 0.00% 
Day 1 Metronidazole 88.7 0.011 97.66% 
Day 2 Metronidazole 28.0 0.011 97.66% 
Day 3 Metronidazole 26.7 0.026 94.48% 
Day 6 Metronidazole 19.1 0.001 99.79% 
Day 7 Metronidazole 6.3 0.035 92.57% 
Day 8 Metronidazole 4.1 0.018 96.18% 
Day 9 Metronidazole 4.7 0.02 95.75% 
 
As can be seen from this data, an efficacious amount of drug can be delivered for up to 1 
week from a 5% loaded depot, and a 10% loaded depot delivers efficacious levels of drug 
for longer than 9 days. 
 
Paclitaxel 
Taxanes, and paclitaxel in particular, have taken a leading role in chemotherapy over the 
recent decade.  This expansion of use is largely due to the efficacy of paclitaxel in 
treatment of a wide range of solid tumors
298
.  This drug moves to block mitotic activity 
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by interference with the formation of microtubules
299
, thus preventing cancer cell 
division.  However, due to the prevalence of significant side effects, paclitaxel is almost 
always used in a low dose compared to that of other bioactive agents
300
.  This need for a 
precise drug concentration combined with the important nature of the drug indications, 
make paclitaxel an important drug for quantification.  HPLC is uniquely suited for the 
low levels of drug used as well as the common use of paclitaxel with other drugs and 
excipients such as Chremophor EL®
298,301
.  The hydrophobic nature of the drug does 
necessitate different mobile phase ratios than the other described drugs, but hydrophobic 




Paclitaxel-free base, free of excipients, was determined to be best analyzed through the 
gradient method of 50 to 65% ACN over a time of 10 minutes.  With this method, a peak 
was found at approximately 6.55 minutes.  This peak was also determined to have a best 
absorbance for analysis at 230 nm.  A standard curve was then prepared using a sample 
solution injected at different injection volumes, resulting in an R
2 
value of 0.999.  The 
standard curve is presented in Figure 5.12. 
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Figure 5.12: Paclitaxel standard curve at 230 nm 
This method was repeatable; however paclitaxel release in aqueous systems reveals poor 
results.  The largest obstacle to testing in similar manners to those used for previous 
drugs lies in the lipophilic (non-water soluble) nature of the drug.  For this reason, release 
studies performed in the traditional manner resulted in sub- analyzable amounts of drug 
release.  It was postulated that the introduction of a non-aqueous solvent component, such 
as ACN, into the release medium could allow visualization of paclitaxel release by 
increasing the solubility of the drug in the medium.  However, this idea was rejected due 
to two main concerns; (1) the drug medium would be less indicative of the physiological 
environment and (2) the introduction of additional solvents could adversely affect the 
degradation of the OC system and exhibit an inaccurate release profile.  For these 
reasons, the only applicable method of analysis was that of an extraction study.  To 
perform an extraction study, the extraction must be clarified and the efficiency must be 
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determined.  To determine the extraction efficiency of paclitaxel from the OC system, 
three samples were prepared of 1 weight percent paclitaxel.  Each of these samples was 
then submersed in 5 milliliters of acetonitrile (ACN) and placed in a 37°C incubator 
shaker.  After 90 minutes the gel and drug were completely dissolved.  A volume of 5 
milliliters of HPLC grade water was added to each of the extraction vials.  Following this 
addition, the solution became a cloudy mixture due to solubility issues with both the drug 
and polymer.  Subsequently, the samples were centrifuged at 10,000 RPM for 20 
minutes.  A clear supernatant was achieved, extracted and filtered through a 0.45 µm 
Acrodisc® filter.  These three eluents were then run in triplicate for each extraction using 
the HPLC.  Results of this analysis are shown in Figure 5.13. 
 
Figure 5.13: Paclitaxel extraction efficiency study (n=3) 
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Figure 38 shows that the paclitaxel extraction is relatively consistent with an efficiency of 
42.85 percent (n=9, 1 standard deviation = 1.04).  However, due to this low efficiency it 
was decided to postpone studies where release would be determined by the remaining 
drug in the gel. 
 
Tobramycin 
Many serious infections within the body require specialized antibiotics.  Tobramycin is 
often used to combat difficult infection such as osteomyelitis
302
 and other serious gram 
negative bacillary infections
303
.  This aminoglycoside is similar chemically to a sugar 
complex but presents challenges for HPLC analysis as it lacks a chromophore
302
.  
Because of this, pre-column derivatization techniques are often employed to make this 
drug visible to an associated UV detector
303,304
.  The method used in this test is similar to 
that presented by Lai of Varian chromatography systems
304
. The pre-column 
derivatization employed involved the preparation of a 0.25 w/v solution of tobramycin in 
a 60/40 v/v ACN/water solvent. Simultaneously, a solution of orthopthaladehyde (OPA) 
in 0.1 v/v% 2-mercaptoethanol/borate buffer (0.4 M, 10.4 pH) was prepared.  These two 
solutions were combined in a 1:1 volume ratio and allowed to react for 1 hour.  At 1 hour, 
the solution was filtered through 0.45 µm filter and analyzed via HPLC. 
 
Tobramycin sulfate salt was successfully prepared for HPLC analysis through a pre-
column derivatization as described.  A pre-column derivatization was required due to the 
lack of a chromophore on the tobramycin structure.  Analysis of the tobramycin complex 
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was determined to be best performed using the gradient method of 5 to 95% ACN over a 
time of 20 minutes.  With this method, a peak was found at approximately 6.15 minutes.  
This peak was also determined to have a best absorbance for analysis at 254 nm.  Other 
peaks, resulting from the agents involved in the pre-column derivatization, present in 
chromatogram were omitted from standard curve analysis.  A standard curve was 
prepared of a sample solution injected at different injection volumes, resulting in an R
2
 
value of 0.99.  The standard curve is displayed in Figure 5.14. 
 
Figure 5.14: Tobramycin standard curve at 254 nm 
The reaction used to prepare the HPLC visible complex is time sensitive, so analysis of 
tobramycin visibility was performed.  A sample was tested for response at 30, 90, 150 
and 320 minutes post reaction initiation.  Results can be seen in Figure 5.15. From this 
information it was determined that analysis should take place in the first hour following 














Following this evaluation, a release study was performed for tobramycin from OC4 at 
both 5 and 10 weight percent mixtures.  The results of this work can be seen in Figure 
5.16. 
 
Figure 5.16: Release of tobramycin from OC4 gel systems (n=3, error bars indicate 1 
standard deviation) 
The results from this study are interesting in that, while tobramycin releases from the OC 
system, the results are different than those of any other drug studied.  Before much is 
made of the difference however, it should be noted that much of the abnormality can be 
explained by the necessary use of a pre-column derivatization.  The wide variation seen 
in post day 1 samples can easily be explained; samples could not be run at the exact same 
time due to the use of an auto sampler system.  For this reason, sample 1 and sample 3 of 
a triplicate were analyzed as much as an hour apart which, as seen in Figure 40, can cause 
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considerable differences in HPLC values reported.  Also, the day 1 results should be 
carefully scrutinized as the low values point to difficulty with the pre-column 
derivatization.  With these items in mind, tobramycin can be incorporated into and 
released from the OC system, but a better method of analysis should be found to allow 
quantification.   
 
Carboplatin 
Carboplatin is highly interesting for this work due to the fact that it is both a 
chemotherapeutic and a water soluble drug.  As discussed previously in Chapter 1, 
carboplatin is employed in a wide array of tumor treatments and would be an ideal model 
chemotherapeutic for such a platform technology.  Interestingly, carboplatin and the other 
platinum drugs show great difficulty in analysis through RP-HPLC.  Their hydrophilic 
nature, as well as the platinum complex, makes binding to hydrophobic C8 and C18 
columns difficult.  With this knowledge in hand, a reverse-phase HPLC method was 
sought for carboplatin. 
 
Carboplatin-free base was determined to be best analyzed through an isocratic method of 
5% ACN over a time of 10 minutes.  Gradient methods proved difficult due to the high 
water solubility of the drug, and a percentage of 5 % was required.  Even with this highly 
aqueous mobile phase, the retention times were barely resolved from the solvent peak.  
With this method, a peak was found at approximately 2.22 minutes.  Despite attempts at 
other mobile phase compositions, no better resolution was found.  The peak was 
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determined to be capable of analysis and was determined to have a best absorbance at 
240 nm.  A standard curve was then prepared of a sample solution injected at different 
injection volumes, resulting in an R
2
 value of 0.9999.  A standard curve is shown in 
Figure 5.17 
 
Figure 5.17: Carboplatin standard curve at 240 nm 
Despite the difficulties with resolving the carboplatin from the solvent injection front, an 
excellent standard curve was prepared, lending credence to the acceptability of the 
method.  This success lead to the incorporation of carboplatin in an OC9/PEG system 
both with and without the additive SW2.  These samples were subjected to a typical 
release study, and the results of this study can be seen in Figure 5.18. 
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Figure 5.18: Release of carboplatin from OC9 gel systems (n=3, error bars indicate 1 
standard deviation) 
These exciting results indicate that carboplatin can be released from the OC systems and 
the release can also be controlled.  Both groups have an acceptable amount of standard 
deviation within readouts at specific time points, but more interesting is the fact that the 
inclusion of the SW2 additive in the system allows a semi-linear release of the drug, 
visualized alone in Figure 5.19. 
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Figure 5.19: Release of carboplatin from an OC9/PEG/SW2 gel system (n=3, error bars 
indicate 1 standard deviation) 
This release shows great promise for treatments of narrow therapeutic range drugs such 
as chemotherapeutics.  Specifically, if this in vitro data could be carried over into an in 
vivo setting, such a treatment could allow a constant exposure of the tumor to drug as 
well as a mitigation of side effects seen by the patient. 
 
Conclusion 
The data presented in this chapter points to the potential of the OC system as a platform 
delivery system.  Multiple drugs, antibiotics, antifungals, and chemotherapeutics, of 
much different chemistry were incorporated and released from the OC system. Also seen 
form the data, multiple drugs can be analyzed from a single HPLC apparatus.  
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Furthermore, each drug has a well-defined and reproducible analytical method.  Each 
method has been determined to be efficient for the respective drug, and robust with an R
2
 
value of greater than 0.99. 
 
Of most value within this chapter are the in vitro release results of carboplatin from the 
OC9/PEG/SW2 system.  This relatively linear release over 3 weeks, a typical 
chemotherapeutic regimen, could provide a very important approach to treatment of solid 




















THE USE OF THE OC SYSTEM TO DELIVER CARBOPLATIN IN AN ATHYMIC 
NUDE MOUSE MODEL 
 
In previous chapters the ground work has been laid for the translation of a promising in 
vitro performing system to the in vivo setting.  The idea of being able to introduce a 
system capable of continuously delivering a chemotherapeutic agent while maintaining 
efficacious drug concentrations holds great promise in the field of chemotherapy.  To 
examine the potential efficacy of the OC system, further testing was required beyond the 
previously described characterization.  This chapter outlines the use of the OC system in 
delivering carboplatin in an athymic mouse model. 
 
The Murine Model and the Relation to the OC System 
The murine model is a typical model used for early in vivo studies.  A very robust and 
cost-effective model, mice can be used for protocols ranging from toxicity studies to 
tissue response visualization.  For use with the OC system, the vision is to use a murine 
model for a tumor response study.  Specifically, tumors will be induced in the mice, 
treated with the OC system, and monitored for tumor response.  While a straight-forward 
plan, many variables must be considered, starting with the specific mouse strain upon 
which to perform studies. 
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The mouse strain chosen for this work was the Athymic Nude-Foxn1
nu
 (Harlan 
Laboratories, USA).  These mice present an interesting combination of attributes as they 
both lack a thymus, and therefore lack lymphocytes, but also are hairless.  Both of these 
attributes are important for the proposed study and present advantages over other strains.  
The genetic manipulation of the mice to prevent the formation of a thymus is valuable for 
induction of tumors.  The lack of T and B cells prevents the mouse immune system from 
attempting to prevent the adherence of tumor cells implanted into the body.  Accordingly, 
attribute cancer cell lines such as OVCAR-3 can be injected into athymic mice and 
tumors can be cultivated in the subjects
305
.  This tumorigenicity allows early stage tumor 
treatment models before proceeding to larger, more costly, animals. 
 
The induced genetic mutation of athymic mice is the hairless nature, or nudity, of the 
strain.  This lack of hair is valuable in that it allows direct observation of the epidermis of 
the subject.  This can be valuable for monitoring of injection sites and surrounding tissue 
for inflammatory and immune response as well as the observation of subcutaneous 
artifacts.  These artifacts can be either the induced tumors or devices implanted by 
researchers.  In the instance of this work, the formation and macroscopic stability of the 
OC system can be observed in vivo following subcutaneous implantation.  Female mice 
were selected because an ovarian cancer cell line was used.  For all these reasons, the 
female Athymic Nude-Foxn1
nu 
murine model was chosen for this work.  
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Following the identification of the animal model for this project, the assays were 
identified.   First, following inducement of tumors, tumor progression would be 
monitored.  Many studies use methods such as fluorescing tumor lines and systems such 
as the IVIS XR Lumina (Perkin-Elmer, USA) to quantify the relative florescence 
between animals.  The use of this system however has many potential pitfalls, and a 
simpler, transcutaneous caliper measurement was identified.   Not only is this method 
more cost effective and robust, it has been employed successfully by our group in past 
studies
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.  For these reasons, tumor size as measured by ellipsoid caliper measurement 
was chosen for tumor progression monitoring.  The ellipsoid caliper method includes the 
taking of 6 diameter measurements around the circumference of the ellipsoid shaped 
object and the averaging of these 6 measurements to reach a single composite value. 
 
Gel permeation chromatography (GPC) was chosen to monitor the degradation of the OC 
system following implantation.  Dichloromethane (DCM) was identified as a solvent 
capable of solubilizing the majority of the OC system and allowing quantification of 
molecular weight before and after insertion.  Also, histology was chosen to help identify 
activity in the tumor microenvironment.  Following excision and immersion fixation in 
formalin, tumors were to be processed and examined using two immunohistological 
stains.  Apoptosis and cell proliferation at time of excision were identified as important 
variables showing tumor behavior and progression.  Apoptosis imaging would be 
performed using the TUNEL assay kit (Invitrogen, USA) and cell proliferation analysis 
would be performed using the PCNA visualization kit (Invitrogen, USA).   
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With thought given to the eventual study, a pilot study was conducted to address what 
level of drug would be tolerated by the animals when delivered through the OC system.  
This preliminary work was also used to verify the assays chosen for the study as well as 
evaluate other potential metrics.   
 
Preliminary Work 
To most effectively treat the induced tumors, the maximum tolerated dose of carboplatin 
capable of being delivered from the OC system was determined.  Such a dose would be 
the optimal concentration to use for the treatment of animals where a tumor had been 
induced as it would be the dose most likely to have an effect on the tumor without 
causing systemic morbid toxicity to the subjects within the study.  For this reason a five 
mouse study was undertaken to determine an approximation of the therapeutic window.   
 
To determine the concentration required, the literature was surveyed for the median lethal 
dose (LD50).  Literature values generally agreed with mouse intravenous LD50 values of 
around 90 mg/kg and intraperitoneal LD50 values of 150 mg/kg
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.  As the desired site of 
implantation was subcutaneous, the intraperitoneal value was chosen as a better predicate 
value to use for these studies.  Thus, using a value of 150 mg/kg and an average female 
mouse mass of 20 grams (0.02 kg), an LD50 value was calculated at 3 mg per mouse.  
Using this as the estimated LD50 values, mice were chosen to be tested at 15 mg, 10 mg 
and 3 mg if the 15 and 10 mg mice showed toxicity. 
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Initially, the 15 mg subject was chosen for initial testing.  To calculate the volume of OC 
system with 5 wt% carboplatin required to reach this dosage, the density of the OC 
system was measured.  This measurement yielded a density of 1.142 g/ml.  Using this 
density, a 250 microliter injection was calculated to deliver 14.275 mg of drug.  Due to 
the limitations of the injection system in quantitating delivery, a 250 µl injection was 
accepted as a reasonable amount to allow accurate delivery rather than an injection for 
exactly 15 milligrams of carboplatin. 
 
With the injection volume calculated at 250 µl, gel preparation was initiated.  OC9, PEG 
400, SW2 and carboplatin were all removed from storage and placed in a chemical hood.  
Materials were mixed in a method similar to previously described methodology with 
minor exceptions.  In order to allow injection into the mice subjects, sterilization was 
necessary.  Sterilization by filtration is a common method for injectable elements, but the 
viscous nature of the OC system makes this problematic, time consuming, and wasteful.  
Gamma irradiation and ethylene oxide sterilization are options for larger scale batches 
and studies, but were not viable scenarios for the given work. For this reason, dry heat 
sterilization was chosen.  All polymeric components were checked for viability at 130°C, 
and found to be acceptable at this temperature.  The literature available for the drug 
carboplatin did not indicate heat stability at this temperature and was therefore not 
subjected to the heat sterilization, but rather carboplatin was assumed sterile due to the 
nature of the drug.  Thus, the polymeric components were subjected to a 130°C 1-hour 
cycle in a dry heat oven.  Following this treatment, the gel was immediately transported 
 133 
to an isopropyl alcohol and irradiation sterilized biosafety cabinet and allowed to cool to 
room temperature.  Following cooling, the carboplatin was introduced into the mixture 
and the system was mixed thoroughly by pestle and mortar within a sterile field.  
Following homogenous mixing, the system was transferred to the non-needle end of a 
sterile 1 ml BD luer-lok syringe capped with a 16 gauge needle and allowed to flow to fill 
the syringe. 
 
Material was transferred the following day to Godley-Snell Research Center (GSRC, 
Clemson University, Clemson, SC) where the subjects were housed.   Mouse A was 
anesthetized and injected in the subcutaneous space of the abdomen.  The injection was 
performed without issue and the system visibly formed subcutaneously through the 
hairless mouse skin, see Figure 6.1.  Seepage through the injection site was present but 
minimal.  The mouse regained consciousness and was mobile and unaffected.   
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Figure 6.1: Image of depot deposited in Mouse A (24 hours post injection) 
 
The subject was checked and examined on day 1 and no ill effects were noted.  The 
mouse was visually checked each subsequent day with no illness noted.   However, on 
day 7 the animal was found dead.  The mouse had perished quickly and the corpse was in 
poor condition when found.  Internal organs were misshapen and swollen; the liver of 
mouse A is presented in Figure 6.2 as an example. 
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Figure 6.2: Liver from Mouse A swollen and visibly diseased 
The depot was not present in large quantities in the necropsy and therefore is postulated 
to have dissipated.  Such rapid dissipation would explain the rapid exposure of the 
internal organs to carboplatin and the subsequent rapid deterioration of the subject.  No 
signs of systemic infection were seen by the attending physician and cause of death was 
suggested as carboplatin toxicity.  Interestingly, the mouse appeared to have been 
accepting nourishment until close to the time of death.  The mouse had only lost ~2 
grams despite the poor condition of the corpse, and the gastrointestinal (GI) tract showed 
fecal emboli throughout the entire system.  This further strengthens the argument of a 
rapid degeneration of the animal. 
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In order to examine the behavior of the gel system in vivo, HPLC analysis of the 
harvested remnants was employed.  For this analysis the small amount of gel retrieved 
from the corpse was placed in a vacuum box and dried to a constant weight.  Once 
constant weight was achieved, the gel/tissue complex was subjected to a drug extraction 
as described in previous chapters.  The resultant eluent was then analyzed via HPLC.  A 
peak was seen at a retention time similar to the carboplatin in vitro studies, indicating that 
there was 0.39 mg of carboplatin in the 82.4 mg sample (0.5 wt%).  However, there were 
issues with the given analysis.  These issues include: (1) the assumption that the excised 
mass was entirely gel, which is unlikely as tissue was intimately joined to the gel sample, 
even after cleaning and (2) the assumption that the entire peak response seen in the 
chromatogram was carboplatin.  To address concern (2), a photodiode array detector 
(PDA) was employed to compare the nature of the response peak generated to that of the 
standard curve employed in the in vitro studies.  A response of “not identical” was the 
outcome of the PDA spectrum comparison.  This does not indicate that the compounds 
represented by the PDA are completely different, simply that the compounds cannot be 
claimed as identical. Hence, the carboplatin extracted from the gel could be degraded 
from the in vivo experience, or even the extraction preparation, and caused an altered 
PDA signal.  Regardless, the HPLC analysis of this gel was determined to be non-viable 
and the decision was made to perform future evaluation of gel using GPC to examine 
molecular weight effects over the course of the study. 
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Following the toxic exposure visualized in mouse A, mouse number B was treated with a 
175 µl injection of the OC system.  This treatment equated to roughly 10 milligrams of 
dose, or greater than 3x the literature LD50.  The OC system was prepared in standard 
fashion as previously described; however, a smaller gauge needle (20 gauge) was 
employed to create a smaller incision site in the subject.  Injection was also performed in 
the rear flank in this subject, to attempt to limit the body cavity volume exposed, see 
Figure 6.3.   
 
Figure 6.3: Hind flank placement of polymer depot (Mouse B 6 days post implantation) 
Mouse B awoke from treatment and was ambulatory within seconds.  The subject never 
experienced any evident ill effects from treatment and survived with no weight loss for 
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28 days.  No signs of infection or injection site irritation were seen during study.  The gel 
depot was evident and in place at the injection site for the complete duration of the study, 
see Figure 6.4.  No internal organ damage was visualized upon scheduled necropsy. 
 
Figure 6.4: Mouse B following euthanasia (21 days post implantation) 
Following this promising result, mouse C was treated with an identical 10 mg delivery 
sample.  The mouse appeared healthy for the first 5 days but exhibited mass loss at day 5 
and was found to have lost ~40% of body mass by day 6.  The subject was euthanized 
according to Institutional Review Board protocol using isofluorine gas.  During necropsy 
no internal organ damage was noted nor any signs of infection.  The polymer depot was 
also perfectly formed and intact, as can be seen in Figure 6.5. 
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Figure 6.5: Mouse C at sacrifice (6 days post implantation) 
The cause of death was deemed to be lack of nutritional intake, with probable cause being 
lack of appetite as a side effect of treatment. 
 
Following this subject loss, mice D and E were treated with 50 µl injections, which 
deliver approximately 3 mg, or roughly the published LD50, of the drug. Neither mouse 
exhibited any ill effects throughout the study and maintained weight for the duration of 
the study.  Both polymer depots remained formed in the hind flank for the duration of the 
study.  Following sacrifice, liver and kidney from mouse D were immersion-fixed in 
formalin (10%), and subsequently prepared for staining.  Both organs were stained with 
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hematoxylin and eosin (H&E) to allow visualization of organ response at a cellular level 
in both tissues.  Images taken from both organs can be seen below at objective 
magnifications of 10x and 40x in Figure 6.6. 
 
Figure 6.6: In clockwise order from top-left (1) Mouse D kidney at 40x (2) Mouse D 
kidney at 10x (3) Mouse D liver at 10x (4) Mouse D liver at 40x 
As can be seen, and confirmed by a licensed pathologist, no evidence of toxicity is 
evident.  This indicates that the carboplatin released from the 3 milligram systems was 
not distributed in large enough concentrations systemically to cause negative liver or 
kidney response on a cellular level. 
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To further understand the behavior of the OC system in this model, gel harvested from 
mouse E was subjected to GPC analysis with DCM as the mobile phase.  A physically 
cleaned gel sample from mouse E was prepared along with four other samples via a 
dissolution and filtration process (0.45 µm acrodisc filter).  The other four samples 
examined were (1) a remnant sample of the prepared gel that had not been subjected to 
the in vivo environment, (2) a neat (polymer only) OC9 polymer sample, (3) a neat SW2 
polymer sample, and (4) neat PEG400. As expected, the glycolide heavy SW2 would not 
dissolve in the DCM solvent of the GPC (a fluorinated solvent, such as 
hexafluoroisopropanol (HFIP), based GPC system was not available for analysis).  
Therefore prior to filtration, insolubilized material could be visually seen in both OC 
system samples and the neat SW2 sample.  Following filtration all samples were run.  
Results can be seen below. 
 
Figure 6.7: GPC results of OC system following mixing but prior to injection 
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Figure 6.8:GPC results of OC system extracted from murine model 
 
Figure 6.9: GPC results of neat OC9 polymer 
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Figure 6.10: GPC results of neat PEG 400 
 




From these results it can be seen that the OC system does experience degradation when 
subjected to the in vivo environment.  The neat OC9 polymer exhibits an Mn of 14185 
while the post-in vivo sample exhibits an Mn of 8393. This relates to the in vitro 
degradation numbers referenced in earlier chapters and suggests that the polymer 
composition is biodegradable.  Also, the PEG peak present in the pre-in vivo gel (Figure 
50) is not present in the post-in vivo gel.  This strongly indicates that the PEG had left the 
construct.  Figure 54 is included to show that all variables have been considered and that 
the post-in vivo peak cannot be any polymer other than OC9, as SW2 is not visible on a 
DCM GPC.  A summary of the results of the preliminary work are presented in Table 6.1. 
Table 6.1: Results of Preliminary Animal Studies 
Mouse Dose Result 
A 15 mg/ 250 µl 
Found dead on day 7.  Massive apparent 
damage to internal organs. 
B 10 mg/ 175 µl Survived entire 21 days with no ill effects. 
C 10 mg/ 175 µl 
Euthanized on day 6 following ~40% loss of 
body mass due to lack of nutrition. 
D 3 mg/ 50 µl Survived entire 21 days with no ill effects. 
E 3 mg /50 µl Survived entire 21 days with no ill effects. 
 
From this work it was evident that no clear window of treatment could be identified, 
especially in this statistically underpowered study.  While promising results were seen 
with mouse C and in the 3 mg mice, no clear window of dosing was found.  Also, a 
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dosing above 3 milligrams would raise the probability of success in tumor response 
model studies.  For this reason a larger pilot study was conducted. 
 
Cell Culturing and Testing of Efficacy with Carboplatin Eluents 
Concurrently with other preliminary activities, OVCAR-3 cells were acquired from 
ATCC (USA).  The specific cell line acquired was NIH:OVCAR-3, ATCC catalog No. 
HTB-161.  These ovarian adenocarcinoma cells were sourced originally from humans 
and have been used in multiple studies for xenografts over the past 30 years
305
.  In one 
study provided by ATCC, tumors developed within 21 days at 100% frequency (5/5) in 
nude mice inoculated subcutaneously with 10
7
 cells. These cells are a biosafety hazard 1.  
The cells were provided frozen and thus were thawed to allow for use.  Thawing was 
performed by gentle agitation in a 37°C water bath, and vial was decontaminated using 
70% ethanol.  Vial contents were then transferred to a centrifuge tube containing 9.0 ml 
complete culture medium and spun at approximately 125 xg for 5 to7 minutes.  Pellets 
were resuspended with medium prepared as per manufacturer’s instruction
305
.  Medium 
for this cell line was prepared through combining ATCC formulated RPMI1640 Medium 
with 0.01 mg/ml bovine insulin and fetal bovine serum to a final concentration of 20%. 
Cells were then incubated at 37°C in a 5% CO2.  Medium was renewed every 2 to 3 days 
during cell use.    
 
Following the successful cultivation of cells, OVCAR-3 cells were plated at a seeding 
density of 37,500 cells/cm
2
 in a 12 well plate.  Once seeded the cells were exposed to free 
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carboplatin in aqueous solution at a calculated 2x the half maximal inhibitory 
concentration (IC50).  The cells were monitored against controls through 
photospectrometry.  Using this methodology, a 66% decrease was seen in cell count 
against the control.  From this data it is reasonable to assume that the OVCAR-3 cells can 
be cultured in sufficient numbers for implantation and will likely be susceptible to 
carboplatin presence in vivo.  The cell line was frozen for maintenance until a tumor 
study could be mounted. 
 
Full Pilot Study 
In order to better define the upper threshold of the therapeutic window, a pilot study was 
performed.  In this study 20 mice were divided into 5 groups as seen in Table 6.2. 
Table 6.2: Groups and Subjects for the Pilot Study 
Groups Mouse Treatment 
1 1,2,3,4 No treatment received 
2 5,6,7,8 
175 µl of unloaded OC system for 
each subject 
3 9,10,11,12 
175 µl of 5wt% loaded carboplatin 
(~10 mg dose) 
4 13,14,15,16 
150 µl of 5wt% loaded carboplatin 
(~8 mg dose) 
5 17,18,19,20 
100 µl of 5wt% loaded carboplatin 
(~6 mg dose) 
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The study was conducted in such a way as to examine the OC system independent of 
carboplatin, as well as at three levels of carboplatin loading.  Thus, the OC system could 
be ruled out of serious consideration as a toxin and the experimental variable, drug 
loading, could also be examined. 
 
To quantify differences between groups, four variables were identified for monitoring 
during the proposed study.  Animal mass, gel molecular weight, complete blood count 
(CBC), and liver/kidney histology were all identified as important metrics of 
performance.  Animal mass was measured in grams weekly and at death as a measure of 
health and nutritional intake. CBC testing was performed on animals where possible to 
determine whether anemic conditions were present as a result of treatment as well as 
immune response and lymphocyte presence in the circulating blood.  GPC and histology 
were performed on every animal as previously described in the preliminary studies. 
 
A single batch of OC system was prepared for the entire animal study, using described 
methodology.  The delivery system had never been prepared on this scale before but no 
significant issues were seen during preparation. Gel was divided into syringes for each 
separate group.  It should be noted that the placebo gel for group 2 was segregated prior 
to the integration of the carboplatin to assure absence of the bioactive agent.  All twenty 
treatments were performed in succession and no significant difficulties were seen during 
injection.  Needles were not changed in between mice of the same group to preserve gel.  
All animals awoke from anesthesia and showed no visible signs of impediment. 
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No difficulties were seen until day 6 when two mice, #15 and #16 were found to have 
expired overnight.  In the next two days, Mice #11, 12, 19 and 20 were all either found 
dead or euthanized due to veterinary concerns as per protocol. The remaining 14 mice 
showed no signs of afflictions or weight loss, with many of the experimental mice 
gaining weight as can be seen in Table 6.3. Within the table, groups are color coded for 
easier identification. 
Table 6.3: Subject Weights during Course of Study 
Mouse Initial Weight (g) 
Weight Day 7 
(or prior) 
Weight Day 14 Weight Day 21 
1 23 24 24 24 
2 22 21 22 21 
3 24 24 26 24 
4 22 23 25 25 
5 21 22 23 22 
6 22 22 23 23 
7 22 23 22 23 
8 22 23 24 24 
9 21 21 22 21 
10 23 24 26 26 
11 24 14* - - 
12 24 16* - - 
13 21 22 23 22 
14 21 21 21 21 
15 19 13ᵻ - - 
16 23 16ᵻ - - 
17 20 21 23 23 
18 23 24 25 24 
19 21 15ᵻ - - 
20 22 13* - - 
*Mice euthanized at or before day 7 – Weight taken at euthanasia  
ᵻ Mice found dead at or before day 7- Weight taken when found  
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GPC was used to examine the effect on polymer molecular weight following in vivo 
implantation.  This data can be seen in Table 6.4.  It should be noted that there are no 
values for group 1 as no polymer was present in these animals. 
Table 6.4: Results of GPC Data from Mice Within The Study 
Mouse Final Viable Day Molecular Weight (Mn) Group Average (n=4) 
1 21 - 
- 
2 21 - 
3 21 - 
4 21 - 
5 21 9623 
9833.25 
6 21 10433 
7 21 9445 
8 21 9832 
9 21 1218 
7563.25 
10 21 9465 
11 6* 10488 
12 7* 9082 
13 21 1240 
5846.5 
14 21 7654 
15 6 ᵻ 6910 
16 5 ᵻ 7582 
17 21 7497 
7805.25 
18 21 7683 
19 7 ᵻ 8470 
20 6* 7571 
*Mice euthanized ᵻ Mice found dead  
 
The polymer groups which contained drug appear to have exhibited more degradation 
than the other groups present in the study.  This point can likely be attributed to the fact 
that the presence of the bioactive agent lowered the local pH of the construct.  A lower 
pH is known to increase hydrolysis and hence hydrolytic degradation.  Also, as the drug 
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leaves the construct, the avenues and volume within the construct would increase, 
allowing water access and increasing hydrolysis.  Perhaps the next most interesting facet 
is that the values of the polymer in the earlier perishing subjects does not vary 
significantly from those of the mice that survived the entire study.  This is interesting as 
one would expect hydrolysis to be an ongoing process, with those samples exposed to 
hydrolytic conditions longer to be more degraded.  There are two samples, from mice 9 
and 13, that were notably degraded but that did run the entire course of the study; these 
are the exception to the rule.  It would be interesting to see if the initial degradation is a 
factor influencing the PEG evacuating the construct.  This could be a significant 
contributor to the hydrolytic process and is a common variable across all groups. 
 
All mice were exsanguinated at euthanasia and blood was provided to AnMed medical 
center (Seneca, SC) for a complete blood count.  Exsanguination was not possible with 
the three mice found dead, as noted in Tables 6.5 and 6.6 on the following pages, which 
show the results of the CBC analysis.  Note that ‘-‘ indicates that no blood was collected 
for a CBC and that ‘NR’ denotes complications with testing at the testing site resulted in 















5.7 8.4 14.4 813.6 
Top End (1 STD) 7.4 9.1 15.3 924 
Low End (1 STD) 4 7.7 13.5 703.2 
1 None Yes 2.5 5.44 12.3 586 
2 None Yes 7.9 5.96 12.1 777 
3 None Yes 8 7.22 12.2 773 
4 None Yes 6.3 7.38 12.3 523 
5 Polymer Only Yes 6.3 7.18 13.6 230 
6 Polymer Only Yes 5.3 6.58 12.2 953 
7 Polymer Only Yes 5.9 6.98 13.2 954 
8 Polymer Only Yes 7.1 6.16 11.2 545 
9 10 mg Carbo Yes 4.1 6.86 13 NR 
10 10 mg Carbo Yes 5.9 6.44 12.1 440 
11 10 mg Carbo Yes 1.6 8.21 14.1 NR 
12 10 mg Carbo Yes 0.6 7.38 12.5 126 
13 8 mg Carbo Yes 4.9 7.92 15 805 
14 8 mg Carbo Yes 4.2 6.07 10.9 640 
15 8 mg Carbo No - - - - 
16 8 mg Carbo No - - - - 
17 6 mg Carbo Yes 5.4 6.19 11.9 675 
18 6 mg Carbo Yes 6.4 7 14.4 551 
19 6 mg Carbo No - - - - 
20 6 mg Carbo Yes 4.8 7.7 13 NR 
Note: WBC = White Blood Cell count, RBC = Red Blood Cell count, HGB = 








Table 6.6: Selected Results of CBC Testing (White Blood Cell Makeup) 
Mouse Treatment Segs# Lymph# Mono# Eos# 
Reference Values 18.90% 77.90% 1.50% 1.90% 
1 None 0.6 1.9 0 0 
2 None 2.8 4.7 0.2 0.2 
3 None 2.6 4.9 0.5 0 
4 None 2.6 3.3 0.2 0.1 
5 Polymer Only 1.8 4.5 0 0 
6 Polymer Only 3.3 1.7 0.2 0.1 
7 Polymer Only 2.4 3.1 0.1 0.3 
8 Polymer Only 2.8 0.1 4 0.2 
9 10 mg Carbo 1.3 2.7 0.1 0 
10 10 mg Carbo 1.2 4.7 0 0 
11 10 mg Carbo 1 0.6 0 0 
12 10 mg Carbo 0.5 0.1 0 0 
13 8 mg Carbo 1.2 3.6 0 0 
14 8 mg Carbo NR NR NR NR 
15 8 mg Carbo - - - - 
16 8 mg Carbo - - - - 
17 6 mg Carbo 1.8 3.4 0.2 0 
18 6 mg Carbo 2.4 3.2 0.6 0.1 
19 6 mg Carbo - - - - 
20 6 mg Carbo 3 1.8 0 0 
Note: Segs#= Neutorphil count, Lymph# = Lymphocyte count, Mono# = Monocyte count, Eos# = 
Eosinophils count 
 
Across this study, many items bear evaluation.  From an experimental standpoint, it is 
evident that larger animal groups are required.  In group 4, the 8 mg dosage group, only a 
single CBC was gained at the end of the study making comparisons across groups 
difficult if not impossible.  With that said, some observations can be made about the data 
as a whole or between other groups.  First, almost all mice, including the controls, 
exhibited anemic or close to anemic counts of red blood cells (RBCs).  This can likely be 
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attributed to smaller sample groups but bears noting.  Next, in the animals that perished 
but from which blood was taken (#11,12, and 20), white blood cell (WBC) counts were 
low, especially in #11 and #12. This could indicate an increase in carboplatin release into 
the systemic tissue as the blood and circulatory system would be the primary carrier for 
this systemic distribution.  Also, there were reduced platelet counts in the samples from 
#11, 12, and 20, further evidence of a potential systemic toxicity.  Lastly and important to 
note, Table 6.6 data shows a marked increase of non-lymphocyte WBCs.  The presence 
of large number of neutrophils (segs# as noted on CBC), monocytes, and eosinophils in 
the polymer control group 2, indicates an immune response outside the normal range.  
While signs of irritation and immune response were not noted macroscopically, it appears 
that the introduction of large amounts of polymer into the mice did elicit an immune 
response.  This should be carefully monitored in future studies to ensure the 
biocompatibility of the system. 
 
Finally histological analysis was conducted on all twenty mouse liver and kidneys.  Mice 
organs were excised and fixated using immersion techniques in 10% formalin.  Tissues 
were then trimmed, transferred to cassettes and embedded in paraffin wax.  Samples were 
then sectioned using a microtome and stained. Using H&E staining, tissue sections were 
examined in conjunction with a licensed pathologist.  No differences nor signs of toxicity 
were seen between groups.  Representative images from livers and kidneys of both 
groups are provided below. 
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Figure 6.12: Liver histology images (H&E staining) of mice 1, 5, 9, 16, and 20.  Images 






Figure 6.13: Kidney histology images (H&E staining) of mice 1, 5, 9, 16, and 20.  Images 




No signs of cellular toxicity was seen in either set of tissue samples.  Normal cell activity 
was seen in the liver sections provided as well as in the kidney samples.  Some tubular 
distortion can be seen in Figure 6.13, but this is not excessive for mouse kidney samples. 
 
Discussion 
This pilot study provides many answers as well as questions.  The primary purpose of this 
study, to delineate an upper threshold of treatment, does not appear to have been met.  
Two mice perished from each of the experimental groups, which indicates that the LD50 
of the treatment is somewhere within the range analyzed.  There were not, however, large 
enough groups of subjects to fully elucidate the differences between the experimental 
groups.  It can be assumed however that at 3 mg dosing, as seen in the preliminary work, 
that reduced toxicity will be seen.  Perhaps groups can tolerate 3 mg dosing from this 
system with limited morbidity, which would already be an improvement over the free 
drug LD50 of 3 mg. 
 
The desired OVCAR-3 strain of cells was successfully cultured.  In addition, the cells 
could be cultured in the relatively large quantities required for injection and future tumor 
xenografting.  Most importantly, the OVCAR-3 cells were shown in vitro to be 
susceptible to carboplatin treatment, indicating that a murine model using an OVCAR-3 
xenograft would be able to show quantitative tumor regression when exposed to 
necessary quantites of carboplatin. 
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While the “polymer only” injected mice showed no signs of outward distress, irritation, 
or immune response, the CBC work on these mice showed some troubling facets.  There 
were signs of a systemic immune response (eosinophil presence, etc.) which indicate that 
the materials were not fully tolerated.  While no biomaterial can be fully inert, this is a 
part of the system which bears further scrutiny.  Despite the presence of the immune 
response cells, no outward toxicity or debility was noted in the mice.  It also bears noting 
that the depot themselves were roughly 1% of the mouse’s body mass, and so would 
represent a very large presence within the corpus.  In future studies, histology can be used 
at the implant site to examine tissue response and ensure that the immune response is not 
overactive as well as check for the formation of fibrous capsules around the implant site. 
 
The CBC results and histology samples are somewhat contradictory with respect to 
systemic toxicity.  From the liver and kidney H&E stains, both organs appear to be 
functioning normally throughout the subjects of the study.  However, the CBC white 
blood cell and platelets values indicate a different picture of decreased viability.  The 
liver and kidney are described as the organs of toxicity for systemically distributed 
carboplatin.  However, in the study they appear to be healthy even in otherwise clearly 
sick mice.  The drug very likely is not being systemically administered in large quantities, 




This hypothesis is further encouraged by the observation of the GI tract in the mice that 
perished within the study.  All mice which were deceased prior to day 21 were found to 
have significant damage to the GI tract, some with visible blood drainage from the anus 
and vagina prior to death.  These organs are among the areas most closely proximal to the 
injection site, and if excess drug was diffusing outward from the site, without reaching 
the liver or kidney, the GI tract would be a logical substitute for this toxicity.  Also, 
disruption of the GI tract could cause animals to cease eating due to disrupted appetite.  
These mice in turn would become weaker and therefore become more likely to perish.    
 
Furthermore, the mice were housed in pairs as behavioral science shows us that animals 
housed with a partner for interaction will more accurately portray a real world scenario.  
This is interesting when viewed in the light of the fact that all 6 mice that perished were 
sets of two housed together.  Nowhere in the study was there a pair of mice where one 
died and one lived.  Also, each of the mouse pairs that died were the later of the groups in 
terms of injection, and a single syringe and needle was used to inject each mouse.  This 
could mean that gel and drug could have been left on the outside of the epidermis 
allowing the cage mates to lick/ingest material in normal cleaning and social interaction.  
The effect that these materials would have directly on the GI tract following ingestion is 
difficult to predict but could explain the significant differences in GI health between 
animals within the same groups. 
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This last thought touches on another facet of the study that requires attention, the 
injections into the animals.  First, the use of the same needle for an entire group to save 
polymer introduced significant variables throughout the study.  If a single animal had 
been diseased an entire experimental group could have been lost.  Also, the luer-lock 
syringe set-up did not allow accurate injection as the 1 ml syringe was graduated in 0.02 
ml or 20 µl markings.  This made it very difficult to attain the desired accuracy for the 
system.  Also, as these devices are designed for delivering liquids, the gels used in this 
study did provide some issues mechanically with injection.  Lastly, the gels required 
loading the night before treatment and so the gel system was at rest in the needles 
overnight prior to treatment.  It cannot be assured that the system did not self-segregate 
with the PEG 400 causing the preferentially held drug to migrate to the later injection 
areas, resulting in a larger than anticipated actual carboplatin dose in the later mice of a 
group.  Further, it is assumed that the entire polymer system was mixed homogenously by 
hand using a mortar and pestle.  This process had been shown to be effective in previous 
studies on a smaller scale, but could have been lacking with the large quantities required 
for this study. 
 
It should be noted that a significant assumption from this study was the actual LD50 
value.  No free carboplatin injections were performed and actual subcutaneous values are 
not readily available in the literature.  The calculated value based on the IP values from 
the literature does provide an educated guess as to the value but intravenous mouse 
values are significantly lower (almost ½) and as such the actual subcutaneous LD50 could 
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be lower than expected.  This would indicate that the system is more successful at 
increasing the maximum tolerated dose than initially thought.  
 
This research does indeed combine the fields of controlled delivery and chemotherapy in 
a step forward.  The results suggest an increase in the LD50, albeit unquantified, of 
carboplatin tolerated within a mouse model.  This in turn indirectly signifies that the drug 
is released in lower quantities over a period of time, allowing the mouse subjects to better 
tolerate the dose.  The system however is far from complete with many significant 
hurdles remaining to make a clinically viable product. 
 
The results of the study bring to mind significant questions, not the least of which is the 
validity of the mouse model.   The behavioral aspects alone discussed previously make 
the results of the mouse model difficult to interpret, and also significant questions have 
been brought to light recently about the translational ability of murine research
308
.  The 
subject is becoming so prevalent that it has made its way into the mainstream media, 
recently appearing in the New York Times
309
. While this study incorporated an adequate 
and cost effective model for early screening exercises, future project critical studies 
should be performed on larger more clinically relevant models.  
 
One significant drawback of the mouse model is the inability to test and model more 
complex medical problems and treatments.  For example, one method of chemotherapy 
gaining wide spread acceptance in the clinic is transarterial chemoembolization, which 
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murine models have difficulty modeling. In this procedure, the tumor is accessed through 
the main arterial stalk which supplies the vasculature of the malignancy.  The agent is 
then delivered via a catheter, port or other device
310
. The agent then uses the vasculature 
of the tumor itself to fully irrigate and perfuse the target and thus efficiently and 
accurately deliver the desired pharmaceutical payload.  This delivery route affords many 
advantages over systemic delivery, such as efficiency and reduced systemic toxicity, as 
well as offers the best opportunity to distribute the maximum amount of drug to the 
malignant tissue. Multiple clinical studies have shown the potential efficacy of such a 
procedure against hepatocellular cancer
311,312
. This procedure is performed traditionally 
with a concentrated drug solution, but recently microparticles and drug-eluting beads 
have been examined
311,313
.  One such product, HepaSphere®, uses microspheres to not 
only treat the malignancy but also to occlude the arterial blood flow and thus act as an 
anti-angiogenic
314
. The ability to not only deliver desired agents as well as prevent 
primary blood supply to a region makes polymeric systems attractive in this application. 
Such methods hold great promise for treating mid to late stage cancers in difficult 
locations such as the hepatic system and could provide excellent uses of the OC system. 
 
Before larger scale studies can be undertaken it is important to understand that the system 
still does require further screening in a mouse system.  Further work should include a 
statistically relevant (n=18) second pilot study of mice injected with a 3 mg dose of the 
drug.  This study would show the tolerance of this treatment and could be used to 
distinguish some of the behavioral/study design variables discovered.  Also, concurrently 
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it is suggested to perform a maximum tolerated dose study aimed at the definition of the 
upper threshold of the therapeutic window for free carboplatin injections in the 
subcutaneous region for these mice.  This would allow a better idea of the increased drug 
delivery capability of the system. 
 
Following this, and assuming an acceptable rate of tolerance of the 3 mg mice across the 
group, the model would be ready for tumor bearing studies as suggested initially.  Within 
this study further assays could be included to fully elucidate the biological processes 
under examination.  First, histological analysis at the implant site is suggested, in addition 
to the PCNA and apoptosis tumor histology.  This assessment would be valuable for 
understanding the cellular immune response elicited by the OC system.  Also, organs 
such as the gastrointestinal tract and ovaries, in addition to the liver and kidneys, should 
be examined by histological means for signs of cellular distress.  Also, perhaps most 
importantly, pharmacokinetics (PK) work should be performed to attempt to quantify the 
release of drug from the construct.  If there is drug being released systemically, PK work 
would allow quantification and would provide an idea of the release rate of the bioactive 
agent from the construct. 
 
Thus the OC system and similar technologies hold great promise in the ongoing battle 
against cancer.  Such technology could one day not only increase patient compliance and 
reduce healthcare costs, but also make chemotherapy more tolerable to the patient.  In 
effect, patient tolerance could be made similar to the administration of any common 
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antibiotic such as penicillin by maintenance of the drug concentration within the 
therapeutic window.  This dissertation is meant to be a humble addition to the wealth of 
work being put forward in this area and, if successful in the improvement of one person’s 






















The presented work serves to further integrate the fields of chemotherapy and controlled 
delivery.  The different combinations of the polymer, diluents and additives serve to 
provide a range of release of a water soluble drug from 3 to greater than 45 days, thus 
allowing the potential for addressing of a large number of clinical indications.  Also, the 
OC system was shown capable of release of the chemotherapeutic carboplatin in a 
relatively linear manner over a period of 3 weeks, the course of a typical 
chemotherapeutic regimen.  Finally, the OC polymer system was examined in an in vivo 
model and tolerance of the non-drug loaded system was exhibited.  Preliminary work 
helped to show that mice would tolerate levels of treatment greater than the 3 mg 
indicated by the literature as well as the effective formation of the system in the 
subcutaneous region of all 20 mouse subjects.  The system was also shown to be 
absorbable and that the absorbable by-products did not cause death or incapacitation in 
the 3 weeks of observation.  A tumor cell line, OVCAR-3, was identified, cultured, and 
proven susceptible to the chosen drug carboplatin in vitro at 2x the half maximal 
inhibitory concentration.   
 
The polymer system is shown to be promising for use with chemotherapy.  The ability to 
replace once per 3 week exposure regimens with a constant release of drug holds great 
clinical potential.  The ability to deliver drugs in this manner could not only increase 
tumor response to chemotherapy and increase survival metrics in patients, but also limit 
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the inherent side effects of such therapy.  This work has laid the foundation for future, 
larger, statistically significant studies wherein the tumor response of the system can be 






















RECOMMENDATIONS FOR FUTURE WORK 
 
The following items are suggested for future studies: 
 
 A larger, more statistically significant, maximum tolerated dose study should be 
performed to further define the therapeutic window.  A sample size of at least 18 
specimens is suggested per group, with dosing ranging from 3 mg to 15 mg. 
 
 A study should be performed to determine the free carboplatin, e.g. not in the OC 
depot, maximum tolerated dose to offer a quantifiable control group in future studies. 
 
 Other assays should be incorporated in future studies. These assays include: 
o Immunohistochemistry at tumor sites to show cell proliferation (a metric of 
tumor growth) and cell apoptosis (a metric of anti-neoplastic effectiveness). 
 
 Histology, including simple hematoxylin and eosinstaining, should also be performed 
on other organs beyond those examined in this research, such as the brain, 
gastrointestinal tract and ovaries as well as at the implant site. 
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 Phamacokinetics should be examined for carboplatin release in vivo to allow 
quantification of release, examination of drug build-up in the surrounding tissue, and 
systemic circulation of drug. 
 
 A larger animal model should be investigated for future animal studies. 
 
 
 The OC system should be examined for treatment of other conditions, such as 
diabetes, patient compliance, inflammation reduction and long-term disease control, 
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